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Head and neck squamous cell carcinoma (HNSCC) is a devastating disease. Despite 
therapeutic advancements, little change in 5-year survival has been made for patients with 
HNSCC. To improve therapy, a better understanding of the underlying biology is needed. Recent 
results suggest that cancer-associated fibroblasts (CAFs) drive disease progression. CAFs 
comprise the most abundant microenvironment cell type in HNSCC, and robustly support the 
cancer. Yet, little is understood of the underlying biology of CAFs. We sought to investigate the 
biological mechanisms mediating CAF-facilitated HNSCC progression. To our surprise, CAFs 
demonstrate significant upregulation of autophagy compared to normal fibroblasts (NFs) from 
cancer-free patients.  Autophagy is fundamentally involved in cell degradation, but emerging 
evidence suggests a role for autophagy in cellular secretion. Thus, we hypothesized that 
autophagy-dependent secretion of tumor-promoting factors by HNSCC-associated CAFs may 
explain their role in malignant development. In support of this hypothesis, we observed a 
reduction in CAF-facilitated HNSCC progression after blocking CAF autophagy. Assessment of 
CAF-conditioned media after autophagy blockade revealed levels of secreted IL-6 and IL-8, and 
other cytokines to be modulated by autophagy. We identify that HNSCC induces fibroblast 
autophagy through basic fibroblast growth factor, IL-6, and IL-8. Although autophagy is 
implicated in other cancers, little is known about autophagy inhibition in HNSCC. Thus, we 
assessed the therapeutic potential of targeting autophagy in HNSCC preclinical models. In a 
CAF-HNSCC mouse xenograft model, pharmacologic inhibition of Vps34, a key mediator of 
autophagy, enhanced the antitumor efficacy of cisplatin. Our results establish an oncogenic 
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Few maladies cause morbidity and mortality as great as head and neck cancer. Each year, 
500,000 new patients are diagnosed globally with this disease (Torre et al., 2015). Both the 
global incidence and US incidence remain unchanged over the past three decades (Cancer 
Collaboration, 2017). The five-year survival rate is less than 50% (Braakhuis, Leemans, & 
Visser, 2014). Current treatment strategies founded in ablative surgery, cytotoxic chemotherapy 
and radiation cause patients to suffer significant morbidity. With dismal outcomes such as these, 
there is great need to develop better treatments for patients suffering from this disease. 
Head and neck cancer comprises tumors originating from the mucosal surfaces of the oral 
cavity, pharynx and larynx. Of these, over 90% arise from proliferating squamous cells 
(HNSCC, head and neck squamous cell carcinoma). The remaining 10% develop primarily from 
salivary glands, and a small prevalence of sarcomas (Peng, Grogan, & Wang, 2014), 
paragangliomas (Pellitteri et al., 2004), and neuroblastomas (Carey et al., 2017). Alongside being 
the most prevalent, HNSCC is also the deadliest.  
Etiologically, tobacco, alcohol, and human papilloma virus (HPV), comprise the primary 
risk factors for HNSCC. The non-viral causes, tobacco and alcohol, have long associated with 
HNSCC. Alcohol consumption of greater than 30 g ethanol/day (equivalent to three standard 
drinks (Kalinowski & Humphreys, 2016)) significantly increases the risk of oral cavity cancer 
(multivariable adjusted incidence rate ratio: 6.39) (Maasland, van den Brandt, Kremer, 
Goldbohm, & Schouten, 2014). Smoking tobacco increases risk for oro/hypopharyngeal cancer 
and laryngeal cancer (multivariable adjusted incidence rate ratio: 8.53 and 8.07, respectively) 
(Maasland et al., 2014).  However, as global smoking rates decline (GBD Tobacco 
Collaborators, 2017), the landscape of non-viral oropharyngeal carcinoma has decreased by a 





In contrast, HPV positive oropharyngeal carcinoma incidence has increased by 225% in 
this same period (Chaturvedi et al., 2011). HPV Infection does not associate with tobacco or 
alcohol use, but rather promiscuous sexual history and marijuana use (Gillison et al., 2008). HPV 
has partiality for squamous epithelium in the head and neck, cervix, and anal regions. As a DNA 
virus, HPV incorporates into the host genome, and transforms the host cell with viral proteins E6 
and E7 to inhibit the tumor suppressors, p53 and Rb, respectively (Vidal & Gillison, 2008). As 
such, these tumors present differently, and have a more favorable clinical outcome, than 
carcinogen-induced tumors. 
Globally, other inciting factors include Betel (also known as Areca) nut chewing, Khat 
chewing, and Maté (Goldenberg et al., 2004). These all have a dose dependent effect on cancer 
incidence, and demonstrate mutagenic effects. Additionally, Epstein Barr virus can transform 
cells of the oropharynx, tonsil, and salivary gland, but most commonly affects the nasopharynx 
(Wheeler et al., 2014). However, incidence from these pales in comparison to tobacco, alcohol, 
and HPV.  
The HNSCC Patient 
HNSCC patients are primarily above the age of 40 and male, with a male to female ratio 
of 3:1-8:1 (Marur & Forastiere, 2016). Patient presentation, symptoms, and clinical outcomes 
vary by anatomic site. In the oral cavity, lesions often are self-discovered, as they are easily 
appreciable by physical exam. These lesions present as a thickening of the mucosa, a painless or 
painful mass, or ulcer, and are accompanied by dysphagia and odynophagia (Insalaco, 2017). 
Lesions of the larynx often are more difficult to discover, and present with hoarseness, shortness 
of breath, and stridor on exam (Insalaco, 2017). Tonsilar and base of tongue tumors commonly 





movement (Posner, 2016). Asymptomatic tumors lead to later detection, which confers a worse 
prognosis.  
Prognostic factors at initial diagnosis include tumor staging, current tobacco use, and race 
(Fakhry et al., 2017). HNSCC tumor staging relies on TNM staging guidelines by the American 
Joint Committee on Cancer. The guidelines differentiate patient prognosis into categories 
ranging from 0 (best prognosis) to IV (worst prognosis) depending on tumor (T) characteristics, 
nodal (N) characteristics, and distant metastasis (M). Recently, the guidelines changed with the 
growing rate of HPV-positive HNSCC, and an appreciation for the different prognostic 
consequences of HPV-positivity. Now, p16 immunohistochemistry (IHC) is first used in 
oropharyngeal HNSCC staging considerations (Lydiatt et al., 2017). For all other sub-sites, and 
for p16 negative oropharyngeal tumors, the most significant variable in staging is the presence of 
metastasis (M). Distant metastasis places a patient at Stage IV regardless of T and N stage. 
Tumor size in centimeters at the greatest dimension determines T criteria. Number, symmetry (as 
in contralateral or ipsilateral lymph nodal involvement relative to primary site), and size of 
lymph nodes determines N criteria.  These criteria adequately construct high predictive power for 
approximation of survival of individual patients (Groome, Schulze, Boysen, Hall, & Mackillop, 
2001). Beyond TNM staging, other statistically significant risk factors include race and 
environment, with black non-Hispanics and current tobacco users having significantly worse 
outcomes (Fakhry et al., 2017).  Overall, early detection provides better outcomes to patients. 
Yet, at diagnosis, over 40% of patients have advanced disease with regional node involvement 






The TNM staging guidelines mirror the understood course of disease progression. Our 
current understanding of the disease course arises from histologic observations and a propensity 
for dysplastic lesions to transition into invasive carcinoma. To understand this, an understanding 
of the normal tissue architecture is helpful. In the head and neck, the mucosal architecture varies 
slightly by anatomic sub-site. The lining mucosa of the inner lips, cheeks, soft palate, floor of the 
mouth, undersurface of the tongue, and pharynx is nonkeratinized stratified squamous epithelium 
(Nahirney, 2013). The gingiva and hard palate are lightly keratinized (Nahirney, 2013). The 
dorsal tongue contains many papillae and differs slightly in architecture than other subsites 
 
Figure 1.1-General Histologic Anatomy of the Head and Neck 
Broadly, the head and neck epithelium follow the same anatomical pattern, with different 












within the upper aerodigestive tract (Nahirney, 2013). However, broadly, the mucosa of the head 
and neck follow the same structural pattern (Figure 1.1). 
Most superficially, the multilayered, nonkeratinized, stratified squamous epithelium 
grows from cuboidal basal cells resting on the basement membrane. Superficial squamous cells 
retain their nuclei, however, the density of nuclei decreases as cells migrate to the superficial 
surface. The epithelial basal cells attach to the basement membrane with keratins 5 and 14 
anchoring to a hemidesmosome (Yancey, 2018). The basement membrane consists primarily of 
type IV collagen, laminins, and heparan sulfate proteoglycans (Yancey, 2018). This membrane 
divides the epithelium from the lamina propria. The lamina propria contains a loose, highly 
cellular connective tissue layer primarily containing fibroblasts. Small capillaries, lymph, and 
nerves extend through the lamina propria. Occasional papillae extend from the lamina propria 
into the stratified squamous epithelium to carry capillaries and lymph vessels (Nahirney, 2013). 
In subsites with musculature, the muscularis mucosa lies deep to the lamina propria and 
superficial to the submucosa, muscularis externa, and adventitia (Nahirney, 2013). Within the 
deep layer of the adventitia lie nerves and vasculature, including arteries, veins, and lymphatic 
channels. This structural pattern remains broadly consistent throughout the mucosal layers. At 
the superficial layer, carcinogens routinely encounter the stratified squamous epithelium leading 
to mutation and proliferation of these cells. 
The architecture transitions during disease progression (Figure 1.2). HNSCC is thought to 
begin with an intraepithelial proliferation of squamous cells. This proliferation sometimes 
presents as leukoplakia, a white patch or plaque that cannot be removed by rubbing 
(Warnakulasuriya & Ariyawardana, 2016). Histologically, the squamous epithelium thickens in 







Figure 1.2 – Disease Progression of HNSCC 
 4-NQO murine model demonstrates progression of HNSCC from low grade squamous 
intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), carcinoma in 
situ (CIS, of two types), and invasive squamous cell carcinoma (Invasive SCCa). Tongue with  
H&E stain (10 X CIS and SCCa; 20 X LSIL, HSIL). 
LSIL HSIL
CIS - papillomatous CIS





HNSCC as less than 4% of leukoplakia patients progress to invasive cancer (Einhorn & Wersall, 
1967). The predictor of leukoplakia progression appears to be the severity of dysplasia. 
Dysplastic lesions are more common in the floor of the mouth, and least common in the 
retromolar space (Waldron & Shafer, 1975). This corresponds with commonality of HNSCC by 
subsite (Mashberg & Meyers, 1976). Severely dysplastic lesions are termed carcinoma in situ, 
which represents significant epithelial thickening and increased nuclei throughout the epithelial 
layer; yet, no histologically observable damage to the basement membrane or underlying 
structures occurs.  As such, few cell types from deep layers are involved in early dysplastic 
lesions. 
As carcinoma in situ progresses to invasive squamous cell carcinoma, the epithelial 
growth is thought to infiltrate the basement membrane. However, no direct molecular biology 
has demonstrated this transition. Histologic evidence demonstrates normal mucosa adjacent to 
the invasive tumor with a gradual transition of dysplasia. Molecular evidence demonstrates 
epithelial cells at the malignant surface take on a partial mesenchymal gene signature, that 
corresponds with high expression of MMP-10 and MMP-2 compared to the tumor as a whole 
(Puram et al., 2017). This would suggest these leading edge cells help to degrade the basement 
membrane. With this destruction of normal architecture, the epithelial cells begin to interact with 
many underlying cell types including fibroblasts, adipocytes, nerves, vasculature and numerous 
leukocytes. These microenvironment cells act as a double edge sword: working to both limit 
tumor progression yet also contributing to advanced disease. The proliferating epithelial cells 
modify the microenvironment. This occurs through direct modification of the extracellular 
matrix, and by secretion of numerous factors, which act upon almost all microenvironmental cell 





understood to harbor few (Qiu et al., 2008). Yet, the activated carcinoma associated cells retain 
heritable patterns of activation markers, and a different expression profile compared to non-
activated cells from cancer-free patients (Costea et al., 2013).   
Beyond the initial presentation, HNSCC has a high propensity for recurrence. The 
majority of patients develop recurrent disease, and distant metastases occur in up to 30% of 
patients (Vermorken & Specenier, 2010). Carcinogenic risk factors of HNSCC facilitate field 
cancerization, where multiple primary tumors will develop within the same anatomic region 
(Slaughter, Southwick, & Smejkal, 1953). Molecular biology confirms this phenomenon as 
surrounding normal tissue around the carcinoma also has genetic alterations in the epithelia 
(Tabor et al., 2001). This facilitates a high rate of recurrence, as even adequately resected tumors 
and targeted radiotherapy cannot account for the dysplastic field of carcinogen exposure.  
Overall, the five-year survival rate of patients at initial presentation is less than 50%. 
With such a dismal outcome, specialized treatment requires a multidisciplinary approach 
encompassing head and neck surgeons, radiation oncologists, and medical oncologists, alongside 
speech therapists, social workers, nutritionists and psychologists.  
Current Therapy 
Site, stage, and patient characteristics influence the treatment approach amongst the three 
treatment modalities of surgery, radiation, and chemotherapy. Primarily, surgery and radiation 
are used in early stage disease, while chemotherapy is used in combination with progressed 
stages. As the first and only therapeutic option available for many years, surgery has the longest 
record of accomplishment; thus, this established the head and neck surgeon as the primary leader 
of the care team. However, radiation and chemotherapy offer approaches to microscopic disease 





the primary treatment modality. Each therapeutic approach offers unique outcomes alongside 
distinctive morbidities. 
Surgery 
As the standard of care for nearly all head and neck malignancies, surgery provides 
excellent control of disease. Surgical approach and technique vary widely based on location of 
the tumor, and local aggressiveness (Lorenz, Couch, & Burkey, 2017). For examples, tumors of 
the oral cavity and oropharynx are approached transorally, whereas tumors of the hypopharynx 
and larynx, or regionally involved lymph nodes, are approached by neck dissection. 
Considerations during surgery include cosmetic outcome, and retention of function. For example, 
the surgeon must consider impacts on the airway, swallowing and speech. Successful surgery 
largely depends on negative margins, with a preferred tumor-free margin of at least 3 mm 
(Lorenz et al., 2017). Reconstructive surgery, especially involving microvascular free flaps, has 
advanced considerably in the last 25 years, and thus offers the surgeon much latitude in 
establishing negative margins (Vermorken & Specenier, 2010). With negative margins and 
appropriate reconstruction, patients are unlikely to experience significant functional impacts. 
However, morbidity increases with the extent of surgical procedures. Immediately post 
operation, complications include pulmonary embolism, hemorrhage and aspiration pneumonia 
(Vermorken & Specenier, 2010). Additionally, a comprehensive pain management plan is 
required following surgery. Depending on tumor location, a tracheostomy or gastrostomy tube 
may be considered, which can provide additional comfort (Lorenz et al., 2017). Additionally, 
although cosmesis is a concern to every surgeon, advanced disease is associated with large 
margins and can cause disfiguration. Additional reconstructive surgery provides palliation to 





stage I or stage II disease, and in this population cure rates can reach up to 90% (Vermorken & 
Specenier, 2010).  For patients with advanced disease, combination therapy is recommended. 
Radiotherapy 
Ionizing radiation damages molecules through direct ionization of target molecules and 
indirectly by generating hydroxyl radicals from water (Barcellos-Hoff, Park, & Wright, 2005). 
Ionizing radiation is delivered in fractionated doses of 2 Gy/fraction daily over 6-7 weeks to 
patients with high risk disease, or 1.6-1.8 Gy/fraction in low to immediate risk disease (National 
Comprehensive Cancer Network, 2017). In early stage disease, radiotherapy is appropriate as a 
single agent and can establish effective cure rates at 70-90% (Corvò, 2007). However, in 
advanced disease, radiation therapy only controls about 50% of tumors, and leaves the five-year 
survival rate at 30% (Corvò, 2007). Additionally, patients suffer long term-morbidity with 
complications arising from radiation, such as radiation-induced fibrosis, xerostomia, 
osteoradionecrosis, and trismus (Straub et al., 2015). The morbidity and mortality in patients 
with advanced disease undergoing radiation as a single modality therapy prompted studies in the 
combination of chemotherapy and radiotherapy. 
Chemotherapy 
Chemotherapy has developed extensively for head and neck patients over the last 40 
years. Before the approval of cisplatin in 1978, patients only received palliative therapy with 
methotrexate and bleomycin (Hong & Bromer, 1983; Pitman, Miller, & Weichselbaum, 1978). 
Tumors responded to these cytotoxic agents, but these regimens offered no improvement in 
survival. Although cisplatin offered no improvement of response rate or overall survival 
compared to methotrexate as a single agent (Grose, Lehane, Dixon, Fletcher, & Stuckey, 1985), 





platinum containing combination therapies had the greatest response (Clavel et al., 1987).  As 
such, these trials established cisplatin as a key therapeutic for HNSCC. Cisplatin only improves 
median survival compared to best supportive care by 1-2 months (Morton et al., 1985). 
Additionally, amongst cytotoxic regimens, combination therapy with cisplatin only improves 
median survival by at most 25 days compared to single agent (Colevas, 2006). Thus, although 
cisplatin offered improved response rates, these regimens offered no improvement in survival at 
the cost of a plethora of side effects. 
Of non-targeted chemotherapies, the best regimens consisted of cisplatin combined with 
either fluorouracil or a taxane. These regimens offer comparable response rates and survival, 
whether a taxane or fluorouracil are used (Sacco & Cohen, 2015). These offer a 30% response 
rate to patients, with a median overall survival of 6 to 8 months (Gibson et al., 2005). The advent 
of epidermal growth factor receptor (EGFR) targeted therapy with the monoclonal antibody 
cetuximab offered an improvement in survival, albeit just a 2-month extension compared to the 
cytotoxic regimen (Vermorken  et al., 2008). However, remarkably, this was the first trial since 
cisplatin was introduced three-decades prior to demonstrate improved survival. As such, 
investigators initiated a number of trials targeting the EGFR pathway, such as additional 
monoclonal antibodies panitumumab (Vermorken et al., 2013) and zalutumumab(Machiels et al., 
2011), and tyrosine kinase inhibitors, geftinib (A. Argiris, Ghebremichael, et al., 2013), erlotinib 
(Soulieres et al., 2004), lapatinib (de Souza et al., 2012), afatinib (T. Y. Seiwert et al., 2014), 
dacomitinib (H. S. Kim et al., 2015). However, none of these studies demonstrate improved 
survival compared to cetuximab, and no significant improvements in side effect profile.  
Since the addition of cetuximab to the clinical regimen 10 years ago, only recent 





immune evasion by programmed death ligands (PD-L1 and PD-L2) on the cancer cell, which 
activate the T-cell suppressive receptor programmed death-1 (PD-1) (R. Ferris, 2015). Recently, 
nivolumab, a monoclonal antibody targeting PD-1, demonstrated remarkable results in 
improvement of survival relative to cetuximab, methotrexate or docetaxel (Robert L. Ferris et al., 
2016). Results of another PD-1 antibody, pembrolizumab, corroborate this targeted strategy at 
improving survival and response (Tanguy Y. Seiwert et al., 2016). These recent reports 
demonstrate the clinical potential of targeting additional microenvironment cell types. 
Thus, current treatment of HNSCC stratifies primarily by stage at diagnosis. Early stage 
tumors have a relatively excellent outcome by surgery and radiation alone. However, advanced 
stage tumors require extensive chemotherapy protocols alongside surgery and radiation. These 
protocols center around a cisplatin/docetaxel/cetuximab backbone, which offers, in combination 
with radiation and chemotherapy, a progression free survival of 7.1 months and an overall 
survival of 15.3 months (National Comprehensive Cancer Network, 2017). When the disease 
progresses despite platinum-containing chemotherapy, nivolumab offers a second-line agent 
(National Comprehensive Cancer Network, 2017).  These regimens reflect more than 50 years of 
scientific work, and extend patient quality of life. However, the outcome of HNSCC with even 
the best clinical care is dismal. The best improvement in overall survival is measured in months 
of patient life, not years.  
Preclinical Models-An Avenue to Improved Therapies 
Overall, just three therapies have extended patient life in the past 70 years: cisplatin, 
cetuximab, and PD-1 inhibitors. The lack of effective therapeutics does not reflect the incredible 
responses observed in preclinical results. For example, the proteasomal inhibitor Bortezomib 





however, in the clinic, bortezomib resulted in early progression of HNSCC and trials were 
discontinued (Athanassios Argiris et al., 2011). Dissection of current preclinical models will 
likely reveal the biological mechanisms underlying the dearth of available therapeutics 
The most widely used preclinical model is the HNSCC cell lines. These cells are derived 
from human explants by manual dissociation or enzymatic digestion of the specimen. Nearly 
every anatomic subsite of HNSCC has cell lines derived, and the abundance of available HNSCC 
cell lines contain nearly every pathogenic mutation (Lin et al., 2007). The in vitro techniques 
associated with understanding disease progression, such as proliferation, apoptosis, and invasion 
assessments are widely established, relatively inexpensive and useful for understanding the 
underlying mechanisms within the tumor cells. However, not all tumors can be cultured. The 
success rate of obtaining an epithelial only population from a patient explant is less than 30% 
(Owen et al., 2016). Additionally, pure cultures of HNSCC devoid of other cell types take on 
average 195 days to establish (Owen et al., 2016). This long length of time may confer selection 
pressures not applicable to patient biology. Further, the three-dimensional biology of the tumor is 
lost in the cultured cells. To model the three-dimensional environment, spheroid models allow 
for multidimensional analysis. Soft agar or low attachment plates make these models feasible. 
However, not all cell lines grow in soft agar, and many HNSCC cell lines will not associate in a 
three dimensional spheroid (Lin et al., 2007). This indicates that even three-dimensional systems 
cannot mimic the biology of every patient. These in vitro models are void of other cell types, 
vasculature, and physical pressures associated with a growing tumor.  
To compensate for these deficiencies, animal models are employed to better include the 
dynamic microenvironment. Yet, no animal model perfectly impersonates the human disease. 





tumor explants or cell lines inoculated into nude mice, carrying the Foxn1 mutation (Braakhuis, 
Sneeuwloper, & Snow, 1984; Rygaard & Povsen, 2007). Void of functioning T cells, these mice 
have an attenuated immune system that allows for the grafting of a human tumor. Ectopic 
implantation allows for clear assessments of tumor volume, but metastasis rarely occurs with 
subcutaneous flank tumors. The orthotopic floor of the mouth xenograft offers a model with 
more applicable metastatic characteristics. Orthotopic models offer opportunity for pulmonary 
metastasis and bone metastasis, alongside local invasion and vascular seeding (Dinesman, 
Haughey, Gates, Aufdemorte, & Von Hoff, 1990). Given the anatomic location, monitoring the 
progression of these tumors is difficult without imaging techniques. To provide a better 
understanding of the human microenvironment, patient derived xenografts (PDX) allow the 
direct implantation of a patient tumor, including all stromal components, into a murine host 
(Tentler et al., 2012). PDXs retain much of the genomic and proteomic characteristics of the 
original tumors (H. Li et al., 2016). However, drift occurs in PDXs that is not reflective of 
human HNSCC, for example there is increased expression of AKT and c-MYC (H. Li et al., 
2016). PDX drift is attributed to the human stroma dissipating with successive passaging of the 
PDX, and an enhancement of murine stroma (H. Li et al., 2016). Additionally, all of these 
models develop in immune compromised athymic mice to allow growth of the xenograft.  
Syngeneic, transgenic, and carcinogen-induced models offer a fully functional murine 
immune system. The SCC VII cell line, derived from a spontaneous C3H squamous cell 
carcinoma, is capable of implantation into a syngeneic host (O'Malley, Cope, Johnson, & 
Schwartz, 1997). In these mice, fully functional T-cells offer a dynamic microenvironment 
(O'Malley et al., 1997). Tumors have pulmonary metastasis and bone metastasis as observed in 





progression typical of this disease, and thus a true microenvironment is absent. To overcome 
this, transgenic models offer a mutation model similar to patient disease progression.  Head and 
neck tumors have overexpressed cyclin D1, that leads to dysplastic lesions in the tongue, 
esophagus, and forestomach (Nakagawa et al., 1997). When Cyclin D1 overexpressing mice are 
crossed with p53 heterozygous mice, these dysplastic lesions give way to invasive squamous cell 
carcinoma in the oral cavity and esophagus (Opitz et al., 2002). Transgenic models of HNSCC 
are lacking compared to other tumor models due to the dearth of tissue-specific promoters within 
the anatomic regions affected by this disease. The best promoters to date are of keratin 5 and 
keratin 14, which are epithelial specific to the basement membrane and overexpressed in 
HNSCC (Caulin et al., 2004).  Yet, most epithelial basement membranes express these keratins, 
making this a poor model for the head and neck. The lack of a specific promoter limits transgenic 
models. Carcinogen induced models offer a tissue specific insult, which leads to disease 
progression closely imitating the human course. The nitrate derivative, 4-nitroquinolone (4-
NQO) acts as a mutagen, and can be delivered through the drinking water or direct painting of 
rodent tongues (X. H. Tang, Knudsen, Bemis, Tickoo, & Gudas, 2004). However, this technique 
takes at least 12 weeks to develop tumors, and imaging is required to monitor these tumors as 
they develop.  
Overall, a great number of researchers and a large amount of resources have been 
invested in developing these preclinical models. Each has its own strengths and weaknesses. 
Sadly, few discoveries made in these models translate to better patient outcomes. This is true for 
both head and neck cancer and other cancers. The NCI has assessed the predictive value of cell 





patient response in phase II studies, with the exception of non-small cell lung cancer 
(Voskoglou-Nomikos, Pater, & Seymour, 2003) (J. I. Johnson et al., 2001). So, what is lacking? 
Perhaps, these poor outcomes occur because the human microenvironment is missing. 
The only microenvironment studied with current techniques is the murine microenvironment. 
Intriguingly, the best advancements in patient outcome modulate the tumor microenvironment. 
Surgery seeks to clear the tumor to a margin that retains a normal architecture. Radiation has the 
best long-term effects when a normal, non-fibrotic microenvironment develops. Additionally, 
despite decades of research focused on the rapidly proliferating cancer cells, all 
chemotherapeutic advancements in survival since cisplatin have acted upon the 
microenvironment. For example, cetuximab activates microenvironment NK cells to induce 
antibody-dependent cell cytotoxicity (Jie et al., 2015). Other methods of targeting EGFR within 
the cancer cell, such as gefitinib and erlotinib, have not extended survival. Additionally, 
nivolumab directly inhibits PD-1 on microenvironment T cells, and does not interact with the 
cancer cell (R. Ferris, 2015). Thus, it stands within reason that the microenvironmental 
influences on cancer progression likely equate and may surpass the contribution of cancer cells 
alone. New preclinical studies are needed which incorporate the patient microenvironment.  
Microenvironment 
The environment in which cancer develops dictates a great deal of disease progression. 
True of both the primary site and metastatic niches, the concept of the environmental influences 
on tumor growth has had attention even since Dr. Stephen Paget’s seed-and-soil hypothesis 
regarding metastatic sites (Paget, 1989). However, despite decades of research, much is still to be 
understood about the microenvironment at both the primary site and metastatic niche. The vast 





disease progression. Each cell dynamically regulates the neighboring cells, secreting hundreds of 
factors and altering cell profiles and extracellular matrix composition. Additionally, cells migrate 
in and out of the environment, physical pressures change, gas tensions alter, and blood flow is 
constantly changing. With intratumoral heterogeneity and the plethora of dynamics 
aforementioned, a perfect model of the microenvironment is not within reach of today’s research 
tools. As such, research on the microenvironment pales relative to the vast amount learned about 
 
Figure 1.3 – Examples of Microenvironment Components of HNSCC 





the rapidly dividing carcinoma cells. Yet, the broad role of the microenvironment in disease 
progression has great appreciation.  
The microenvironment consists of cellular and non-cellular components (Figure 1.3). 
Non-cellular components describe the extracellular matrix, physical pressures, gas tensions, and 
chemotactic gradients. The cellular components lead to the functional changes observed in the 
non-cellular components. The six broad microenvironmental cell types are: vascular endothelial 
cells (both blood and lymph), immune infiltrates, nerves, adipocytes, microbes, and fibroblasts. 
Vasculature 
The rapidly proliferating tumor requires a strong blood supply for nutrients and oxygen. 
As the tumor grows, oxygen tension decreases as distance from vasculature increases. 
Determined in lung adenocarcinoma, at a distance of 169 µm away from vasculature, low 
oxygen tension prompts tumor necrosis (Thomlinson & Gray, 1955). In hypoxic regions, 
hypoxia-inducible factors (HIF, particularly HIF1α) are stimulated. These initiate transcriptional 
profiles that lead to two broad outcomes: (1) migration of carcinoma cells towards a more 
oxygen rich environment, and (2) the release of angiogenic cytokines. Of these, vascular 
endothelial growth factor (VEGF-A) is the most widely studied. VEGF-A promotes the 
proliferation of endothelial cells (Karl et al., 2007). Intriguingly, endothelial cells support the 
growth of HNSCC not only through providing a capillary supply, but also by secreting 
interleukin (IL)-6, IL-8 and epidermal growth factor (EGF) (Neiva et al., 2009). This symbiotic 
tumor-promoting relationship explains why VEGF, and HIF1α expression correlate with poor 
clinical outcome (Hoogsteen, Marres, Bussink, van der Kogel, & Kaanders, 2007; Tse et al., 
2007). However, despite a link to clinical outcomes, anti-angiogenic therapy in HNSCC has had 





events, such as bleeding (A. Argiris, Kotsakis, et al., 2013; Machiels et al., 2010; Williamson et 
al., 2010). Thus, intratumoral hypoxia and angiogenesis are important microenvironment 
characteristics in HNSCC; yet, how to target and modulate these phenomes still requires much 
research. 
Although the tumor initiates a rich blood network, only half of malignancies are thought 
to spread through the blood vasculature (Maula et al., 2003). The paradox of a large number of 
circulating tumor cells (7 per 1000 peripheral blood mononuclear cells, equivalent to 
approximately 7000 circulating tumor cells per mL of peripheral blood (Weller et al., 2014)), and 
the dearth of lung metastasis (the first capillary bed encountered by veins) in early disease, 
indicates the importance of other vasculature for metastatic spread. The cervical lymph nodes are 
most often the first site of HNSCC metastasis, and thus highlight the role for intratumoral lymph 
in disease progression (Leemans, Tiwari, Nauta, Waal, & Snow, 1994).  Additionally, 
intratumoral lymph density significantly correlates with clinical outcome (Franchi, Gallo, Massi, 
Baroni, & Santucci, 2004). Lymph endothelial cells are activated by VEGF-C, and VEGF-D, as 
well as other microenvironment factors which stimulate both the carcinoma and vascular 
endothelial cells including: fibroblast growth factor (FGF), hepatocyte growth factor (HGF), 
platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF)(Adams & Alitalo, 
2007).  The vasculature, both blood and lymph, provide vehicles by which cancer cells may 
spread to distant organs through disease progression. 
Microbes 
The role of the microbiome in cancer progression gathers great attention. The vast 
number of microbes contributes to the poor understanding of the role of these in HNSCC 





microbiome. The oral microbiome includes bacteria, viruses, archaea, and eukaryotes, and 
contains more than 1000 different microbes (Dewhirst et al., 2010). Tobacco and alcohol change 
the microbiome, while patients with an HPV infection have a microbiome that clusters with the 
normal population by 16S ribosomal RNA profiling (Leclercq et al., 2014; J. Wu et al., 2016). 
Broadly, patients with HNSCC have different taxa represented compared to healthy individuals 
(Schmidt et al., 2014). Most notably, fusobacteria increase in HNSCC patients (Gong et al., 
2014; H. Wang et al., 2017). Targeting the microbiome to alter disease progression is a focus of 
current study, and no therapeutics target the microbial populations directly, to date.   
Immune Infiltrates 
The most widely studied component of the microenvironment, immune cells actively 
work to diminish the growing epithelial lesion.  The immune microenvironment closely 
intertwines with disease progression. This is exemplified by observations that cancer occurs at 
sites of chronic inflammation, and yet evades the immune system. This is important for clinical 
outcomes as patients with high levels of intratumoral immune infiltrate have a better outcome 
than those whose tumors evade the immune system (Mandal et al., 2016). The immune 
contributions to the tumor microenvironment are vast, as this is a dynamic population of many 
cells, all which uniquely modify their environment. Out of the many immune cell types, T cells 
and dendritic cells compose the primary infiltrates in HNSCC; whereas NK cells and neutrophils 
have less abundance (Becht et al., 2016). Successful tumor progression only occurs if the cancer 
evades destruction by the immune system. 
An immune suppressed microenvironment develops through active evasion of the cancer 
cells. Cancer cells reduce their immunogenicity, and secrete suppressive factors to establish this 





damaged cells by presentation of neoantigens in the human leukocyte antigen (HLA) complex to 
T-cells. However, tumor cells reduce HLA expression, leading to evasion from T-cells. NK cells 
actively seek for “missing self” cells that do not express HLA; however, carcinoma cells secrete 
cytokines such as transforming growth factor-β (TGF-β) to limit NK activation (Viel et al., 
2016). Additionally, cancer cells express a number of immune checkpoints, such as PD-L1 and 
CD80. These establish inhibitory signals on activated immune cells, particularly T-cells, to 
diminish an immune response (R. Ferris, 2015). By reducing their immunogenicity, secreting 
immunosuppressive factors, and expressing inhibitory ligands, HNSCC evades the adaptive 
immune response. 
The innate immune cells within the microenvironment paradoxically increase tumor 
growth and immune suppression. Dendritic cells within the microenvironment typically present 
antigen to activate an immune response. However, TGF-β and IL-10 within the 
microenvironment contribute to dendritic cell suppression, which leads to the secretion of factors 
to differentiate T-cells into regulatory T-cells (R. L. Ferris, Whiteside, & Ferrone, 2006). 
Additionally, tumor associated macrophages are widely present in HNSCC. Yet, these 
macrophages differentiate into the M2 subtype, which correspond with a suppressive milieu and 
increased angiogenesis (Costa et al., 2013; S. Y. Liu et al., 2008).  Overall, a composed immune 
response would keep the tumor at bay. Yet, the tumor suppresses and evades the immune system, 
creating a dysregulated immune environment culpable of cancer progression. 
Cell Populations in Low Abundance 
Compared to other cell types, adipocytes and nervous system cells are poorly studied 
microenvironment components. Although these cells are abundant in the normal anatomy of the 





difficulties with in vitro techniques. Adipocytes float in culture media due to their high lipid 
component, creating difficulties when comparing them with adherent cancer cells (Carswell, Lee, 
& Fried, 2012). Peripheral nerves in the head and neck arise from the cranial nerves and retain 
their nuclei within the brain. Although surgical specimens derived from HNSCC patients may 
contain axonal fragments, these fragments do not propagate without the nucleus. Despite these 
challenges, and low numbers of these cell types within the microenvironment, adipocytes and 
neurons contribute to tumor progression.  
Few studies examine adipocytes within the HNSCC microenvironment. Yet, studies on 
other cancer types, primarily breast, indicate adipocytes function as tumor promoting cells within 
the microenvironment (Duong et al., 2017). Adipocytes in proximity to cancer cells have a 
tumor-promoting secretome, rich in hepatocyte growth factor, which is highly overexpressed in 
the HNSCC microenvironment (Dirat et al., 2011; Knowles et al., 2009; Rahimi, Saulnier, 
Nakamura, Park, & Elliott, 1994). The cytokines secreted from adipocytes increase cancer 
proliferation, migration and invasion, as well as angiogenesis. Additionally, adipocytes provide a 
reservoir for fatty acids necessary for rapid cell proliferation (Kwan et al., 2014; Y. Y. Wang et 
al., 2017). Intriguingly, prolonged exposure of adipocytes to cancer cells results in mature 
adipocytes losing their fatty acid content and exhibiting fibroblast-like morphology (Bochet et 
al., 2013). Histologically, when the tumor invades the surrounding adipose tissue, adipocytes 
decrease in number, and fibroblasts accumulate (Nieman, Romero, Van Houten, & Lengyel, 
2013). Perhaps de-differentiation of adipocytes into fibroblasts occurs, but the mechanisms by 
which this occurs needs thorough investigation. 
Neurons within the microenvironment contribute to pain associated with the tumor as 





VII (facial), both of which provide sensation. As such, HNSCC induces considerable pain 
attributed to cancer cells damaging the neuronal sheath, noxious stimuli within the 
microenvironment, and growth factors stimulating the proliferation of both the cancer and the 
nerve, such as nerve growth factor and brain-derived neurotrophic factor (Roh, Muelleman, 
Tawfik, & Thomas, 2015). Patients with perineural invasion within the HNSCC 
microenvironment have a worse prognosis, with higher rates of recurrence and a significantly 
lowered five-year survival (Fagan et al., 1998). As with adipocytes, a great deal more is yet to be 
understood with microenvironment neurons.  
Fibroblasts 
Fibroblasts comprise the most abundant cell type in the HNSCC microenvironment 
(Becht et al., 2016). Intriguingly, this is juxtaposed against the fact that regions susceptible to 
HNSCC have a relatively shallow lamina propria compared to other epithelial surfaces in the 
body. Nevertheless, these cancer-associated fibroblasts (CAFs) are in large abundance and 
considerably promote disease progression. CAFs take on an entirely different phenotype 
compared to normal fibroblasts (NFs) from the same anatomic location of cancer-free patients. 
Compared to NFs, CAFs promote HNSCC metastasis to distant organs, angiogenesis, and 
immune evasion. Despite the broad phenotypic differences and the clear role of CAFs in disease 
progression, the underlying biology of CAFs is poorly understood.  
Perhaps assessing the role of fibroblasts in normal wound healing facilitates 
understanding these cells within the tumor microenvironment. In fact, cancer might be 
understood as a wound that does not heal (Dvorak, 1986). In normal tissue, fibroblasts exist to 
maintain the extracellular matrix. Upon injury, fibroblasts are summoned in increased numbers 





factor (PDGF), IL-1β, and tumor necrosis factor alpha (TNF-α) (Eming, Martin, & Tomic-Canic, 
2014). Fibroblasts migrate to the site of injury through integrin-mediated adhesion to collagen 
fibrils and fibronectin, and migration can be blocked by targeting each of these components 
(Guido & Tranquillo, 1993; Hsieh & Chen, 1983). At the site, fibroblasts differentiate into an 
activated phenotype (Hinz et al., 2007). This differentiation occurs in response to: (1) increased 
levels of TGF-β, (2) an altered extracellular matrix, and (3) mechanical stress within the 
environment (Tomasek, Gabbiani, Hinz, Chaponnier, & Brown, 2002). The activated fibroblasts 
are termed myofibroblasts, due to their contractile nature in conjunction with an accumulation of 
alpha-smooth muscle actin (α-SMA) within their cytoplasm (Gabbiani, Ryan, & Majne, 1971). 
These myofibroblasts secrete a number of matrix metalloproteinases (MMPs), which degrade the 
extracellular matrix, and tissue inhibitors of metalloproteinases (TIMPs) to keep the degradation 
in check (Soo et al., 2000).   Additionally, myofibroblasts secrete many cytokines to initiate the 
epithelialization of the wound, including: KGF, EGF, and HGF among many others (Eming et 
al., 2014). After successful wound homeostasis, fibroblasts undergo apoptosis, returning to 
normal tissue abundance, however, the mechanisms by which this occurs are not clear 
(Desmouliere, Redard, Darby, & Gabbiani, 1995; H. Y. Zhang & Phan, 1999). Thus, fibroblasts 
promote normal wound homeostasis by infiltrating the site of the wound, degrading the aberrant 
extracellular matrix, and supporting the contraction and re-epithelialization of the wound. 
However, when the wound is caused by rapidly proliferating epithelial cells, fibroblast-
induced epithelialization makes the tumor worse. Our lab and others demonstrate CAFs to 
increase cancer cell proliferation by secretion of HGF (Knowles et al., 2009; Wheeler et al., 
2014).  Additionally, CAFs play a large role in promoting tumor metastasis. MMPs secreted by 





structures and better access to vasculature (Lu, Takai, Weaver, & Werb, 2011).  In vitro results 
demonstrate that squamous cells alone rarely invade into an extracellular matrix, but when the 
epithelial cells are seeded atop fibroblasts, there is significant invasion, with the fibroblasts 
leading the invasive front (Gaggioli et al., 2007). In animal models, HNSCC implanted with 
CAFs demonstrate increased metastasis to the lungs compared to HNSCC alone or HNSCC with 
NFs (Wheeler et al., 2014). Fibroblasts directly affect carcinoma cells to promote disease 
progression. 
Additionally, CAFs modify other microenvironment components and cell types. Beyond 
modifying the extracellular matrix through MMPs and TIMPs, CAFs secrete vastly different 
collagens within the extracellular matrix which facilitate cancer progression (Sok et al., 2013). 
CAFs facilitate immune evasion by increased synthesis of prostaglandin E2, which inhibits T-
cell proliferation (Alcolea et al., 2012; Harris, Padilla, Koumas, Ray, & Phipps, 2002). A number 
of cytokines secreted by CAFs activate angiogenesis within the tumor microenvironment, 
including HGF, IL-6 and IL-8 (Leef & Thomas, 2013). Additionally, preliminary results within 
our lab demonstrate CAFs mediate metabolic adaptions within the carcinoma cells. Overall, 
CAFs modulate nearly all hallmarks of cancer (Figure 1.4).  
Despite such a dynamic contribution to the tumor microenvironment, mechanisms 
underlying sustained CAF activation remain largely enigmatic. Partially, limited understanding is 
a product of poor understanding of why HNSCC is highly fibrotic. Regions most often afflicted 
by HNSCC, for example the floor of the mouth, have a relatively shallow lamina propria with 
scant fibroblasts. Yet, HNSCC ranks among the tumors greatest in fibroblast abundance (Becht 
et al., 2016).  The origins of the abundance of CAFs is unknown. CAFs may originate from rapid 





endothelial cells, smooth muscle cells, or epithelial cells undergoing an epithelial to 
mesenchymal transition (Coen, Gabbiani, & Bochaton-Piallat, 2011; Humphreys et al., 2010; 
Labelle, Begum, & Hynes, 2011; Piera-Velazquez, Li, & Jimenez, 2011). Although there are a 
plethora of hypotheses, the origin and recruitment of CAFs to the tumor is poorly understood. 
Beyond initial recruitment, the sustained activation of CAFs remains unclear. For 
example, CAFs grown in culture for many generations retain their tumor promoting affects 
compared to NFs, indicating a possible genetic or epigenetic change. However, mutations are 
 













































Examples of CAF Contributions 





uncommon in CAFs (Qiu et al., 2008). Whereas epigenetic alterations are routinely studied in 
cancer, little is understood of myofibroblasts epigenetics, and no studies have been conducted on 
HNSCC CAFs. Hepatocytes exposed to TGF-β have a markedly different epigenetic signature, 
and this may be applicable to TGF-β activated CAFs (McDonald, Wu, Timp, Doi, & Feinberg, 
2011). In colorectal cancer, CAFs display a global hypomethylation, with hypomethylation 
occurring in a stage dependent manner (Ling et al., 2016). Direct research into CAF epigenetics 
in HNSCC is lacking, but perhaps epigenetic changes account for the differing phenotype 
compared to NFs. 
 Additionally, although CAFs demonstrate markedly pronounced expression and 
secretion profiles compared to NFs, the underlying anatomy contributing to their secretory 
profile is understudied. These cells have a well-studied phenotype, which activates cancer, but 
the underlying machinery involved in producing this phenotype is not well known. CAFs 
comprise a large component of the HNSCC microenvironment, yet many questions remain about 







Overall, the microenvironment dictates tumor progression. However, microenvironmental 
cell types are not routinely included in HNSCC preclinical models. This may explain the dearth 
of therapeutics that have progressed from preclinical models to effective clinical trials. 
The focus of this dissertation surrounds the aberrantly signaling fibroblasts. These are the 
most abundant microenvironmental cell type, but little is understood of the underlying biology. 
Phenotypically, CAFs are remarkably different from NFs. Previous results within our lab 
demonstrate CAFs promote proliferation and metastasis, and symbiotically communicate with 
the tumor (Wheeler et al., 2014). Despite these pronounced effects, little is known about the 
underlying biology. As such, we sought in this work to understand how CAFs promoted disease. 
What biological pathways within the cell prompted such dynamic differences in disease 
progression?  
Our first observation was that CAFs appear astonishingly punctate when visualized by 
light microscopy (Figure 1.5). This led us to seek characterization of these vesicles. To our 










Figure 1.5-CAFs Have Punctate 
Vesicles throughout Cytoplasm  
Representative light microscopy 
image of punctate vesicles 























Autophagy, since its discovery, is predominantly known as a degradative process. 
Increased autophagosomes in nutrient deprived and stressed cells supports the concept that this 
pathway serves a pro-survival, metabolite-generating role. Mitochondrial structures identified 
within lysosomes led to the name “Self-Eating” (auto-, -phagy), further promoting the 
degradative connotation of this pathway. 
The autophagic machinery is conserved across yeast and mammalian cells. Broadly, the 
pathway comprises the initiation of a double membrane vesicle, which sequesters cellular cargo 
and traffics toward degradation in the lysosome (vacuole in yeast) (Figure 2.1). A catalytic 
cascade initiates the pathway, and nutrient sensors AMPK and mTOR regulate this initiation. 
This cascade leads to enhancement of the double membrane vesicle, which incorporates the 
lipidated protein, LC3. Cargo receptors bind and carry autophagic cargo destined for the 
autophagosome, and facilitate the molecular tethering of cargo to LC3 on the autophagic 
membrane. The fusion of the autophagosome with the lysosome involves specialized SNARE 
complexes. This facilitates the delivery and degradation of autophagic cargo. 
Autophagic Mechanism 
Initiating Catalytic Cascade 
The ULK1/Atg1 (unc-51-like kinase) complex exists as the upstream initiator of 
autophagy (Itakura & Mizushima, 2010; Matsuura, Tsukada, Wada, & Ohsumi, 1997). Nutrient 
sensing mediators, mTORC1 and AMPK, function to govern ULK1 activation.  mTORC1, 
containing mTOR, raptor, and GβL, is sensitive to nutrient conditions within the cell, and is 
exquisitely sensitive to amino acid conditions (Wullschleger, Loewith, & Hall, 2006). Limited 
amino acid conditions repress mTORC1 activity (Sancak et al., 2008). mTORC1 functions to 





regulating ULK1. This occurs through raptor binding and consequential phosphorylation of 
ULK1 under rich amino acid scenarios, limiting ULK1 activity.  
Conversely, AMPK activates ULK1. AMPK assesses glucose concentrations indirectly 
by measurement of AMP/ATP ratios. High concentrations of AMP implicate a low glucose 
environment and this enhances AMPK activity, which in turn, results in activating 
 
Figure 2.1 - Initiating Events in Autophagy  
Three events occur to initiate the development of the autophagosome: (1) a catalytic cascade 
governed by the nutrient sensors, AMPK and mTOR, activates the Beclin-1 complex, which 
initiates the development of the double membrane structure; (2) LC3 is cleaved and lipidated 
in an E1/E2 ubiquitin-like conjugation system, and is incorporated into the double membrane 
on both inner and outer leaflets; (3) p62, or other cargo receptors, bind ubiquitinated cargo 





phosphorylation of ULK1 (J. Kim, Kundu, Viollet, & Guan, 2011).  Additionally, alongside the 
regulation of ULK1 by mTORC1 and AMPK, proteins Atg13 and FIP200 provide a scaffold to 
enhance ULK1 activity to its maximal level (Ganley et al., 2009). All said, low nutrient 
conditions of amino acids and glucose result in signaling cascades, which enhance ULK1 
catalytic activity. 
ULK1 mediates its pro-autophagic effects by phosphorylating, and thus activating, 
Beclin-1. Beclin-1 synchronizes an autophagy-initiating complex. The core components of this 
complex are Beclin-1, Vps15, and Vps34. Vps34 provides the primary agent of this complex’s 
activity (Russell et al., 2013). As the only known class III PI3K, Vps34 regulates the pools of 
phosphatidylinositol 3-phosphate (PtdIns(3)P) surrounding the developing autophagosome 
(Volinia et al., 1995). This pool of PtdIns(3)P is advantageous for other autophagy related 
enzymes to complete the maturation steps. With rare exception (Zhou et al., 2010), Vps34, and 
the pool of PtdIns(3)P it provides, is necessary for autophagic flux (Kihara, Noda, Ishihara, & 
Ohsumi, 2001).  
Despite a defined nutrient sensing catalytic cascade, the actual foundation of the lipid 
components of the autophagosome membrane is poorly understood. Speculation arises if this 
membrane initiates from the Golgi apparatus, mitochondria, recycling endosomes, the plasma 
membrane, secretory vesicles, or the endoplasmic reticulum, with the endoplasmic reticulum 
being the strongest candidate (reviewed in Shibutani & Yoshimori, 2014). Although the concrete 
origin is unknown, the developing autophagosome encompasses a cup-shaped double membrane 
structure, termed the isolation membrane or phagophore (Reunanen, Punnonen, & Hirsimäki, 
1985). Through the remaining development of autophagy, this open-ended structure eventually 





Development of the LC3+ Autophagosome 
LC3 (microtubule associated protein 1A/1B-light chain 3), the mammalian homologue of 
yeast Atg8, incorporates into the developing autophagosome. Originally proposed to regulate 
microtubule assembly (Mann & Hammarback, 1994), LC3 has become the most widely used 
marker of the autophagosome. By sucrose separation, LC3 demonstrates association with only 
autophagosomes and dense lysosomes, and not ER, Golgi, nuclear, plasma, or mitochondrial 
membranes (Kabeya et al., 2000). The unique association of LC3 with the autophagosome 
membrane and with the lysosome, the terminal destination of the autophagosome, has established 
its role as a specific autophagosome marker.   
LC3 undergoes a series of modifications to incorporate this water-soluble protein into the 
lipid membrane of the autophagosome. Within six minutes of translation, LC3 is cleaved into the 
form LC3-I by Atg4 (Kabeya et al., 2000; Kabeya et al., 2004). Although LC3-I is ubiquitous 
throughout the cytosol, a physiological role for this isoform is poorly defined. During autophagic 
flux, an E1/E2 ubiquitin like conjugation system facilitates conjugation of LC3-I with PE 
(phosphatidylethanolamine) to form LC3-II (Kabeya et al., 2004). Atg7 comprises the E1 like 
protein, and Atg3 serves as the E2 like protein (Ichimura et al., 2000). Atg5 and Atg12 enable 
this E1/E2 LC3-II conjugation (Mizushima et al., 2001). Atg5 and Atg12 also conjugate through 
an E1/E2 conjugation system comprising Atg7 and Atg10 (Mizushima et al., 1998). The Atg12-
Atg5 complex facilitates LC3 conjugation by enhancing the function of Atg3 (Hanada et al., 
2007). Atg16 carries the Atg12-Atg5 complex to the developing membrane where the cleavage 
and lipidation of LC3 takes place (Mizushima et al., 2003). Through these cleavage and 





autophagosome. The newly lipidated form of LC3 provides a molecular anchor for autophagic 
cargo within the lysosome. 
Although LC3 is the most widely used marker of the autophagosome, autophagy can still 
occur in LC3 knockout cells. However, in these cells, fusion with the lysosome is impaired, and 
there is an accumulation of autophagosomes (Padman, Nguyen, & Lazarou, 2017). This indicates 
LC3 is not necessary for development of the double-membrane autophagosome, but this protein 
is required for normal flux and final degradation of this pathway. 
Cargo Recruitment 
Cargo destined for the autophagosome can include whole organelles, protein aggregates, 
and even intracellular pathogens. Autophagy cargo receptors contain two broad domains, a cargo 
recognition motif, and a LC3-interacting region. Ubiquitin serves as the most common cargo 
recognition motif. Capable of marking proteins, organelles, and pathogens, ubiquitin serves as an 
adapter to bind these substrates to a cargo receptor. By proteomics, there are 33 proteins which 
could function as cargo receptors based upon their ability to interact with LC3 (Behrends, Sowa, 
Gygi, & Harper, 2010).  
The best understood of these cargo receptors is SQSTM1 (also known as p62). SQSTM1 
directly interacts with LC3, and is degraded under normal autophagic flux (Komatsu et al., 
2007). The ubiquitin binding domain of SQSTM1 allows for the interaction of this protein with a 
large number of autophagic cargo destined for the autophagosome. Additionally, SQSTM1 has 
multiple other protein binding motifs which can allow for the adherence and trafficking of non-
ubiquitinated proteins to either the autophagosome or proteasome (Moscat, Diaz-Meco, Albert, 
& Campuzano, 2006). The LC3-interacting region on SQSTM1 is crystalized, and serves as the 





Beyond SQSTM1, there are four other well-known autophagy cargo receptors. NBR1 
(neighbor of BRCA1) has structural similarity to SQSTM1 in that it binds ubiquitin through a c-
terminal UBA domain (Campbell et al., 1994). NDP52 (also known as CALCOCO2) has a non-
canonical LC3 interacting region (von Muhlinen et al., 2012). This is especially important for the 
degradation of pathogens through autophagy. OPTN (optineurin) traffics proteins to LC3 in a 
ubiquitin independent manner by means of a coiled-coil domain (Korac et al., 2013). NIX (BCL2 
and adenovirus E1B 19 kDa-interacting protein 3-like) has a BH3 domain and acts to recruit 
mitochondria to LC3 for autophagic degradation, also known as mitophagy (Sandoval et al., 
2008). These cargo receptors allow for the selective recruitment of cargo to the developing 
autophagic membrane.  
Degradative Mechanism 
The fusion of autophagosome with lysosome follows an intricate recruitment strategy of 
mediating proteins to form a complex that melds the two lipid membranes (Figure 2.2). The pool 
of PtdIns(3)P generated by Vps34 recruits Ccz1-Mon1 (Caffeine, calcium and zinc 1-Monensin 
sensitivity protein 1) to the developing autophagosome (Hegedűs et al., 2016). This GEF 
(guanine nucleotide exchange factor) recruits the small GTPase Rab7 to the autophagosome. 
Rab7 facilitates tethering of the autophagosome with the lysosome by binding the HOPS 
(homotypic fusion and vacuole protein sorting) complex on the lysosome (Hegedűs et al., 2016). 
Additionally, PLEKHM1 binds the LIR of LC3 on the outer autophagosomal membrane and 
functions to accentuate HOPS-Rab7 recruitment (McEwan et al., 2015). With the 





SNARE complex containing Syn17 (Syntaxin17, a Qa SNARE), USNP (SNAP-29 homologue 
ubisnap, a Qbc SNARE), and VAMP7 on the lysosome (an R SNARE)(Itakura, Kishi-Itakura, & 
Mizushima, 2012; Takáts et al., 2013). This fusion allows for the disbursement of cargo and 
autophagic machinery into the lysosome.  
As the main cellular organelle for degradation, the lysosome concludes degradative 
autophagy (Saftig & Klumperman, 2009). Lysosomal enzymes degrade both the autophagic 
molecular machinery and the cargo they carried. The function of these enzymes depends on a 
 
Figure 2.2 – Degradative Mechanism 
 Fusion of the lysosome and autophagosome is mediated by the recruitment of Rab7 to the 
autophagosome which subsequently binds the HOPS complex on the lysosome. The binding 
of these bring the Qa SNARE, Syn17, on the autophagosome to the R SNARE, VAMP7, on 
the Lysosome. The binding of these two with the Qbc SNARE, USNP, facilitates membrane 




















high proton concentration and the resulting low pH. This pH gradient between the cytosol and 
the lysosome makes for an effective target at the termination step of autophagy, terming these 
agents as lysomotropic. Lysomotropic agents, such as the widely used chloroquine, disrupt the 
pH balance, which prevents the degradation of autophagic components and cargo, and an 
accumulation of the autophagy pathway intermediates. This pathway can also be perturbed by 
looking at the molecular mediators of autophagosome-lysosome fusion. 
Orchestrating a passing of cellular components to the lysosome for degradation, 
autophagic machinery are nearly constant across species. With few exceptions, homologues of 
the molecular machinery exist in all living cells for the adaptation to microenvironmental 
influences. With an understanding of this machinery, experiments have perturbed this pathway 
and identified dramatic results in cellular secretion.  
Autophagy-Dependent Secretion 
Over the past 40 years, a subtle, but growing body of evidence points to an interesting 
function of this pathway in cellular secretion.  Even in Noble Prize laureate Dr. Ohsumi’s 
original report on autophagy in yeast, the outcome of increased autophagy under nutrient 
starvation conditions was enhanced secretion of labeled leucine (Takeshige, Baba, Tsuboi, Noda, 
& Ohsumi, 1992).  Others have demonstrated the fusion of autophagosomes with the plasma 
membrane for the expulsion of cellular cargo (Schweers et al., 2007). Additionally, cells with 
enhanced basal autophagy have a distinct secretome compared to low autophagy cells (Kraya et 
al., 2015). With growing evidence, autophagy serves pleiotropic roles within the cell as both a 
degradative and secretory pathway.  
Autophagy facilitates secretion in both normal physiology and pathology. Understanding 





machinery. Enhancement or attenuation of these components leads to consequential secretory 
alterations. Perturbation of this pathway has identified key signaling molecules and cytokines, 
such as IL-1β and IL-6, which are altered with autophagy (Endo et al., 2017). Even entire viruses 
and bacteria are secreted through autophagic machinery labeled vesicles (Jackson et al., 2005). 
As such, this pathway affects many diseases ranging from cancer to viral infections, asthma, and 
Chron’s disease. With surmounting evidence supporting the implications of autophagy-
dependent secretion, and the lack of drugs targeting this pathway, biologists across disciplines 
will see benefit from the a new understanding. 
Secretory Mechanism 
Autophagy-dependent secretion stems from observations of the unconventionally 
secreted protein Acb1 (Acyl-CoA Binding Protein, dictyostelium homologue: AcbA). 
Functionally, Acb1 is released from pre-spore yeast cells to induce sporulation (Anjard & 
Loomis, 2005).  Under autophagy enhancing conditions, such as low nitrogen concentrations, 
cells secrete increased levels of Acb1 (Duran, Anjard, Stefan, Loomis, & Malhotra, 2010). 
Following individual knockdown of autophagy components, Atg5, Atg7, Atg8, and Atg12, Acb1 
secretion significantly decreased, despite constant Acb1 concentrations within the cell. This 
foundational report suggested a role for the autophagosome in secretion of extracellular proteins.  
Intriguingly, Acb1 is a leaderless peptide, lacking a secretion signal sequence. Under 
conventional secretion, an N-terminal signal sequence directs proteins to the endoplasmic 
reticulum (ER) for folding, and then successive modification in the Golgi apparatus to facilitate 
secretion (Reviewed in (Rapoport, 2007)). This signal peptide consists of a positively charged 
amino terminus, a hydrophobic central region, and a cleavable carboxyl terminus, which allows 





all proteins have a secretory signal sequence. However, many proteins do not have this 
cleavable, targeting sequence, even though they are readily detected extracellularly. Notable 
examples include: macrophage migration inhibitory factor (Simons et al., 2011), tissue 
transglutaminase (Zemskov, Mikhailenko, Hsia, Zaritskaya, & Belkin, 2011), and IL-1β (Dupont 
et al., 2011), among others.  
With a foundation in Acb1, most mechanistic work on autophagy dependent secretion 
arises from studies interrogating IL-1β secretion. The initial cloning of this protein identified IL-
1β lacked a secretion signal sequence (Auron et al., 1984). A connection with autophagy arose 
with the observation that IL-1β secretion was enhanced following starvation of bone marrow-
derived macrophages, similar to the enhancement of Acb1 secretion following nutrient starvation 
(Dupont et al., 2011). Knockdown of Atg5 demonstrated autophagy mediates the secretion of IL-
1β (Dupont et al., 2011). Since this finding, the molecular mechanisms involved in autophagy 
dependent secretion, including cargo recruitment, vesicle trafficking, and membrane release, 
have been primarily worked out using IL-1β as the released protein of interest. 
Cargo Recruitment 
A modified autophagosome routes IL-1β for extracellular secretion. This begins with 
cargo recruitment to the developing autophagosome. Mature IL-1β binds to TRIM16 (Tri-partite 
motif 16, also known as ERBBP) (Munding et al., 2006). This IL-1β-TRIM16 complex traffics 
to an autophagy sequestration membrane (Kimura et al., 2017). The sequestration membrane is 
not an autophagosome, but a shuttling membrane necessary for lipidation of LC3-I to LC3-II (M. 
Zhang, Kenny, Ge, Xu, & Schekman, 2015). Without TRIM16, IL-1β cannot arrive at the 






At the sequestration membrane, Sec22b binds the IL-1β-TRIM16 complex. Sec22b 
consists of a longin domain (involved in protein transport to the plasma membrane) and a 
SNARE motif (Y. Liu, Flanagan, & Barlowe, 2004), with this SNARE motif critical to the 
vesicle fusion events involved in IL-1β secretion. Originally identified as part of the vesicle 
fusion machinery involved in COP-II coated vesicle fusion in the ER-Golgi intermediate 
compartment (Mancias & Goldberg, 2007), Sec22b is of particular importance to autophagy. 
Upon knockdown of Sec22b, LC3 lipidation is decreased (Ge, Zhang, & Schekman, 2014). 
Paradoxically, Sec22b depletion leads to an increase in LC3-II levels by immunoblot and LC3 
puncta by immunofluorescence (Kimura et al., 2017; Renna et al., 2011), but no overall 
differences in autophagic flux. Reconciling this finding, Sec22b depletion blocks trafficking of 
lysosomal proteases to the lysosome, thereby rendering the lysosome ineffective (Renna et al., 
2011). With Sec22b depletion, IL-1β secretion decreases (Kimura et al., 2017). Therefore, an 
autophagosome destined for secretion would have LC3-II, Sec22b, and TRIM16 on its cytosolic 
membrane. 
Membrane Fusion 
To fuse with the plasma membrane, the secretory autophagosome undergoes a SNARE 
mediated fusion event. SNARE proteins are tail anchored proteins, which mediate the fusion 
event(Y. A. Chen & Scheller, 2001) . They assemble into a complex of Q (glutamine) and R 
(arginine) SNAREs across assembling membranes to join the acceptor and donor membranes (Y. 
Wang et al., 2016). The R-SNARE, Sec22b, on the secretory autophagosome binds to Qbc-
SNAREs, SNAP-23 and SNAP-29 on the plasma membrane (Kimura et al., 2017). Together with 
Syntaxin-3 and Syntaxin-4 on the plasma membrane, these proteins mediate a SNARE complex 





2017). The fusion of the secretory autophagosome with the plasma membrane facilitates 
secretion of IL-1β. 
The modified autophagosome involved in IL-1β secretion has characteristics similar to a 
degradative autophagosome, but differs in a few key cytosolic membrane elements to facilitate 
the trafficking to the plasma membrane. Similar to the degradative autophagosome, a secretory 
autophagosome has a double membrane labeled with LC3-II. Cargo recruitment in both secretion 
and degradation appear to rely on trafficking of cellular cargo to LC3. However, the destinations 
of the LC3+ double membrane vesicle differ based upon the SNARE machinery coating the 
cytosolic membrane (Figure 2.3). In a degradative autophagosome, Syntaxin17 allows for fusion 
with the lysosome. In a secretory autophagosome, Sec22b facilitates fusion with the plasma 
 
Figure 2.3 – SNARE Machinery Coating 
Autophagosome Destined for either Degradation or 
Secretion   
Degradative autophagosomes are coated with lipidated 
LC3 (LC3-II), and Syn17. Secretory autophagosomes 






membrane. These subtle differences in the cytosolic membrane proteins determine whether the 
contents are degraded or expelled.  
Additionally, the role of the autophagolysosome in secretion remains unclear. Although 
the secretion of IL-1β seems to bypass the lysosome, other secreted cargo depend upon 
lysosomal function. For instance, chloroquine inhibition of the lysosome alters the secretory 
profile of CAFs in a way that mimics Beclin-1 knockdown (New et al., 2017).  Even IL-1β 
seems to rely on the lysosome, as the same group that delineated the mechanism of autophagic 
secretion of IL-1β also demonstrated in an earlier report that Bafilomycin A1, which inhibits the 
acidification of the lysosome, inhibits IL-1β secretion (Dupont et al., 2011). Autophagy-
dependent secreted cargo may all have the same route bypassing the lysosome, but an alternative 
pathway, which incorporates the lysosome, cannot be excluded based on the current data.  
The TASCC (Tor associated spatial coupling compartment) provides an alternative 
mechanism for autophagy dependent secretion, and enhances IL-8 secretion. At the Golgi 
apparatus, the TASCC brings together mTORC1, rough ER, Golgi apparatus, autophagosomes 
and lysosomes (Narita et al., 2011). This creates a dynamic metabolism center functioning to 
sequester material through degradative autophagy to reconstitute new proteins for secretion. IL-8 
and IL-6 were both identified in this compartment, and IL-8 mRNA was detected at the marginal 
regions (Narita et al., 2011). Under autophagy inhibition, the TASCC cannot form, preventing 
the translation of IL-8 and IL-6. This compartment identifies an alternative role of the 
autophagosome in secretion, as some secretory cargo are reliant upon a functioning degradative 
autophagy pathway, but not necessarily a secretory autophagosome. 
Although the best understanding of autophagy dependent secretion comes from 





nascent and could potentially differ with different cargo chaperoned by the autophagosome. For 
instance, there seems to be cross-communication with the exosomal pathway. Exosomal 
fragments derived from prostate cancer cells demonstrate the presence of autophagy markers 
LC3, p62, and others (Hessvik et al., 2016). Within the cell, multivesicular bodies and exosomes 
are targeted to the autophagosome when autophagy increases (Fader, Sanchez, Furlan, & 
Colombo, 2008). This may allow for the fusion of membranes and the directing of an 
autophagosome to the plasma membrane. The mechanisms regulating the cross-communication 
between exosomes, multivesicular bodies, and secreted autophagosomes are ill-defined. 
Despite some remaining questions, this mechanism of secretion is enthralling. Machinery 
once thought to be only involved in degradation now appear to have pleiotropic roles. Alongside 
this, over the last decade, the variety of cargo secreted has expanded to include everything from 
metabolites to full organelles.  
Secreted Factors 
Autophagy dependent secretion offers a wealth of factors extracellularly. These secreted 
components range from inflammatory mediators to granule contents. By perturbing the canonical 
autophagic machinery, researchers identified a number of components depend on autophagy for 
secretion. The list has expanded substantially from the initial identification of Acb1 secreted 
through an autophagy mechanism less than a decade ago. 
Interleukins 
The primary class of autophagy-dependent components are interleukins. As described 
above, IL-1β has been extensively studied in relation to autophagic secretion, and provides the 
main understanding of the machinery involved in secretion. Similarly to IL-1β, the IL-1 family 





bafilomycin A1 or Atg5 knockdown attenuated IL-18 secretion (Dupont et al., 2011). Beyond the 
IL-1 family, other interleukins have demonstrated significant involvement with autophagy, 
notably IL-6 and IL-8. 
IL-6 provides an interesting anecdote in the story of autophagy dependent secretion. 
Multiple groups observe the secretion of IL-6 depends upon autophagy. With Atg7 knockdown, 
IL-6 secretion reduces in pancreatic stellate cells (Endo et al., 2017), fibroblasts (Young et al., 
2009), breast cancer cells (Maycotte, Jones, Goodall, Thorburn, & Thorburn, 2015), and human 
brain endothelial cells (Zhuang et al., 2017). Thus, IL-6 is secreted in an autophagy dependent 
mechanism. IL-6 then feeds back, and further enhances autophagy. Observed in pancreatic 
cancer cells (Kang et al., 2012), and fibroblasts (New et al., 2017), IL-6 provides a fascinating 
feed-forward loop accelerating autophagy dependent secretion.  
Damage Response Mediators 
Although primarily studied in a healthy cell population, autophagy-dependent secretion 
proves important even in apoptotic and necrotic cells. Necrotic cells selectively release HMGB1 
(high mobility group box 1), whereas apoptotic cells retain this immune stimulus within their 
nuclei (Scaffidi, Misteli, & Bianchi, 2002). Upon knockdown of key autophagy proteins, Atg5, 
Atg7, and Atg12, HMGB1 secretion during necrosis ceases. Thus, autophagy dependent 
secretion mediates regulation of microenvironment damage responses. 
Additionally, extracellular ATP release serves as a chemokine to mediate an immune 
response towards a damaged region. For example, following irradiation, ATP released from 
damaged cells, signals immune cells to the region. However, knockdown of Atg5 inhibits ATP 
release and a normal immune response cannot occur (Ko et al., 2014). Chemotherapy treated 





from pharmaceutically damaged cells (Michaud et al., 2011). Therefore, autophagy dependent 
secretion mediates appropriate damage responses by regulating HMGB1 and ATP from 
apoptotic or necrotic cells.  
Secretory Granule Contents 
In a variety of tissue types, secretory granules regulate tissue development and 
homeostasis. Autophagy dependent secretion facilitates a variety of these secretory granules 
from widely different tissue types.  
Intestinal Paneth cells secrete a large number of antimicrobial proteins necessary for both 
innate defense and regulation of the microbiome. Dysregulation of these cells is one feature of 
Crohn’s disease. Atg16 mutations predict susceptibility to Crohn’s disease (Hampe et al., 2006). 
Dysregulation of Atg16 leads to dysfunctional granule exocytosis from Paneth cells (Cadwell et 
al., 2008). Disruption of normal granule exocytosis causes retention of key antimicrobials, such 
as lysozyme, resulting in an incompatible response to bacterial infection (Bel et al., 2017). 
Without autophagy-dependent secretion, normal Paneth cell secretions could not occur. 
In endothelial cells, autophagy dependent secretion of secretory granules allows for 
homeostasis following vascular injury. VWF (von Willebrand factor) assembles long multimers, 
which, when tethered together, provide adhesion of circulating platelets and facilitates clotting. 
Weibel-Palade bodies contain VWF in endothelial cells. With impairment of autophagy, through 
knockdown of Atg5 or Atg7, Weibel-Palade bodies are retained intracellularly, VWF cannot be 
secreted, and there is impaired healing of the vessel wall (Torisu et al., 2013).  
Secretory lysosomes have physiologic importance in tissue homeostasis and immune 
responses. For example, bone resorption relies on osteoclast-mediated secretion of lysosomal 





when autophagy enzymes Atg5, Atg7, Atg4, and LC3 were knocked down or mutated, bone 
resorption dramatically decreased (DeSelm et al., 2011). This provides evidence of the 
involvement of autophagy dependent secretion in trafficking secretory lysosomes. This may 
occur in other myeloid derived secretory cells, such as natural killer cells, which granular 
contents are contained within a secretory lysosome (Lopez-Soto, Bravo-San Pedro, Kroemer, 
Galluzzi, & Gonzalez, 2017).  
Furthermore, mast cells, components of the innate immune response, rely on autophagy 
dependent secretion for degranulation of secretory lysosomes. Mast cells play a crucial role in 
maintenance of the allergic response. Degranulation of these cells releases histamine and other 
cytokines into the microenvironment to mount an immune response. LC3-II localizes with 
secretory granules within mast cells, and is secreted with co-localized CD63, a secretory 
lysosome marker. Knockout of Atg7 results in impaired degranulation of mast cells, and an 
impaired anaphylaxis reaction (Ushio et al., 2011). Autophagic machinery prove necessary in the 
trafficking of granule components during immune response. 
Ranging from intestinal cells, vasculature, osteoclasts, and immune cells, autophagy 
dependent secretion provides an essential homeostatic mechanism of granule release throughout 
an organism. Extensive characterization of the mechanisms of granule release compared to 
cytokine release remains to be studied. However, the core autophagic machinery prove essential 
to this secretory process.  
Extracellular Matrix Components 
Of note, an association of autophagy dependent secretion with extracellular matrix 
components has been observed. In pancreatic stellate cells, which synthesize the pancreatic 





key matrix components are significantly reduced in expression (Endo et al., 2017). These include 
Collagen 1α1, fibronectin1, and periostin (Endo et al., 2017). The role of autophagy dependent 
secretion from fibroblasts of other tissues (New et al., 2017; Young et al., 2009) provides support 
for the concept that extracellular matrix synthesis occurs through an autophagy dependent 
secretory manner.  
Role in Disease 
With such a plethora of factors secreted, autophagy dependent secretion affects both 
normal physiology and pathophysiology. The understanding of autophagy dependent secretion in 
disease has grown primarily out of three disease classes: infection, neurodegeneration, and 
cancer.  
Infection 
Viruses hijack normal cell mechanisms to reproduce, and the autophagic machinery 
provide a fascinating example of this. Early on, picornaviruses, such as polio, were observed in 
double membrane vesicles, with an appearance similar to the autophagosome. Intriguingly, 
poliovirus components 2BC and 3A induce the formation of these double membrane structures 
(Suhy, Giddings, & Kirkegaard, 2000). 2BC directly modifies LC3, allowing its incorporation 
into the membrane (Taylor & Kirkegaard, 2007). Poliovirus then uses the autophagosome like 
membrane as a lipid source during viral replication. Once formed, the LC3 positive double 
membrane vesicles traffic the enclosed viral particles to the plasma membrane, where LC3 
positive vesicles bleb off the host cell surface (Jackson et al., 2005). This creates a secreted 
autophagosome, coated with the host’s own cellular components, but packed with poliovirus 
cargo (much like a Trojan horse). This method of non-lytic viral production significantly 





Poliovirus transmission tightly intertwines with autophagy dependent secretion. With 
Beclin-1 overexpression, poliovirus transmission increases (Y. Chen et al., 2015). Accordingly, 
Beclin-1 knockdown significantly reduces poliovirus yield (Y. Chen et al., 2015). Pharmacologic 
inducers of autophagy, such as rapamycin, enhance poliovirus yield by more than three-fold 
(Jackson et al., 2005). Thus, autophagy dynamics correlate with poliovirus secretion. 
Beyond poliovirus, other viruses undergo such autophagy dependent secretion. 
Rhinovirus and coxsackievirus also exit host cells in vesicles harboring LC3-II (Robinson et al., 
2014). Varicella zoster virus exits the host in a single membrane vesicle harboring LC3, but also 
Rab11, an endocytic marker, which may indicate the convergence of the autophagy and 
endocytic pathways in varicella zoster expulsion (Buckingham, Jarosinski, Jackson, Carpenter, & 
Grose, 2016). Dengue virus induces LC3 puncta, in a matter that relies on Beclin-1 (Mateo et al., 
2013). During dengue virus infection, beclin-1 inhibition significantly reduced extracellular virus 
(Mateo et al., 2013). Within the last decade, this method of non-lytic viral transmission has just 
been uncovered, and much work is still to be done with the exact mechanisms in the transmission 
of each viral type. 
Ejected bacteria also rely on autophagy dependent secretion. Mycobacteria tuberculosis 
and M. marinum expel themselves from the host cell in an ejectosome (Hagedorn, Rohde, 
Russell, & Soldati, 2009). This is a vesicle decorated with LC3 protein that is expelled from the 
cell. The autophagic machinery are recruited to the distal pole of the ejectosome, and facilitate 
bacterial expulsion (Gerstenmaier et al., 2015). When Atg1 (ULK1), Atg5, Atg7, and Atg8 were 
knocked down, non-lytic cell-to-cell transmission of mycobacteria significantly reduced 







Two neurodegenerative conditions, Alzheimer’s and Parkinson’s disease, have long been 
associated with defective autophagy. In both of these diseases, an intracellular inclusion body 
forms: amyloid beta aggregates in Alzheimer’s disease, and α-synuclein inclusions in 
Parkinson’s disease. The dysregulation of autophagy in these diseases was thought to prevent the 
degradation of these aggregates, which led to their abundance within the cell. However, recent 
evidence points to defective autophagy limiting their secretion, which results in intracellular 
accumulation. 
In Alzheimer’s disease, dystrophic neurites have an accumulation of autophagosomes 
(Nixon, 2007). These autophagosomes contain the bulk intracellular reservoir of amyloid beta 
(Yu et al., 2005). Although this finding led to the initial conclusion that the accumulation of 
amyloid beta and autophagosomes resulted from a dysfunctional autophagolysosome, Atg7 
knockout transgenic mice have connected amyloid beta accumulation with a decreased secretory 
autophagy pathway. Atg7 knockout neurons had diminished amyloid beta secretion, and 
reconstitution of Atg7 restored the secretion of amyloid beta (Nilsson et al., 2013). Further, 
pharmacologic induction of autophagy with rapamycin enhanced amyloid beta secretion, while 
inhibition of autophagy with spautin-1 diminished secretion (Nilsson et al., 2013). Thus, 
autophagy influences secretion of amyloid beta in Alzheimer’s disease.  
In Parkinson’s disease, α-synuclein aggregates accumulate within dopaminergic neurons 
(Luk et al., 2012). Both autophagy and the proteasome degrade α-synuclein. In neurons, p25, 
traffics α-synuclein to autophagosomes, while also preventing autophagosome lysosome fusion 
(Ejlerskov et al., 2013). This promotes secretion of α-synuclein containing autophagosomes 





synuclein release (Ejlerskov et al., 2013). Thus, autophagy dependent secretion facilitates the 
secretion of α-synuclein in neurons.  
Cancer 
Relative to normal tissue, cancer tissue of almost all organ sites upregulates autophagic 
flux. Increased degradative autophagy provides a mechanism for renewal of damaged organelles 
and proteins in a metabolically active microenvironment.  Increased autophagy also promotes 
cancer cell survival by facilitating therapy resistance (X. H. Ma et al., 2011). As discussed 
above, autophagy dependent secretion facilitates secretion of cancer-promoting factors, such as 
IL-1β and IL-6. Within the microenvironment, both the cancer cells themselves and stromal 
supporting cells rely on autophagy dependent secretion for progression of the disease as well as 
therapy resistance. 
The dynamics of autophagy dependent secretion in cancer cells is best exemplified by 
differing secretomes between cells of the same cancer site with differing basal rates of 
autophagic flux (Kraya et al., 2015). Genetically paired melanoma cells with differing basal 
levels of autophagy provides a unique material to study autophagy dependent secretomes (Kraya 
et al., 2015). Low autophagy cells had markedly reduced secreted levels of CXCL8, IL-1β, LIF, 
FAM3C, and DKK3 compared to cells with high basal levels of autophagy (Kraya et al., 2015). 
Beclin-1 overexpression provided confirmation in these low autophagy cells that the factors 
secreted were indeed dependent upon autophagy. These factors support tumor progression, and 
allow for useful biomarkers in response to autophagy modulating cancer therapy. 
Autophagy Dependent Secretion Summary 
A secretory pathway conserved across yeast to mammals, autophagy-dependent secretion 





broad implications, our understanding of this pathway is in its infancy, with the molecular 
mediators only partially worked out with IL-1β secretion. As such, few targeted inhibitors exist. 
For example, hydroxychloroquine provides the lone clinically available autophagy 
inhibitor (Benoit Pasquier, 2016). This, and other lysomotropic inhibitors, destabilizes the 
lysosome and prevents autophagosome degradation. Although this may destabilize the TASCC 
and prevent autophagy dependent secretion of IL-8 and IL-6, it also inhibits autophagic 
degradation useful for homeostatic maintenance of the cell. Alternatively, inhibitors such as 
SAR405 and Spautin-1 target autophagy upstream at the Beclin-1-VPS34 complex (J. Liu et al., 
2011; Ronan et al., 2014). Effective at diminishing both secretory and degradative autophagy, 
these cannot differentiate between the two routes for the autophagosome. 
Developing a selective route inhibitor, to better delineate the secretory and degradative 
routes, would provide details of the pathways and vesicle traffickers involved. The primary 
difference in the final destination relies on the differential expression of Syn17 or Sec22b on the 
cytosolic membrane. However, these two proteins function in multiple cellular pathways, and an 
inhibitor solely targeting either of these would be of little use. Perhaps proteomic approaches 
assessing carriers similar to TRIM16, unified cargo carriers that bind both LC3 and Sec22b, 
would be of use. By understanding the binding of cargo carriers to LC3 and trafficking 
intermediate Sec22, an appreciation of the exact cargo secreted through a secretory 
autophagosome could develop. 
Overall, autophagy-dependent secretion proves essential in a wide variety of cellular 
processes with a plethora of factors secreted. Despite clear importance in both normal physiology 





more clear understanding of the molecular mechanisms will facilitate therapeutic development to 
counteract disease and augment normal physiology.  
A Role for Autophagy Dependent Secretion in the HNSCC Microenvironment? 
CAFs derived from HNSCC patients have a punctate, vesicular architecture when viewed 
by light microscopy. Although these puncta typically characterize dying cells, CAFs proliferate 
quickly, and confer many factors to promote disease progression. Given the emerging 
understanding of autophagy dependent secretion, we hypothesized that HNSCC induces CAF 
autophagy, which facilitates tumor-promoting secreted factors. We sought evidence to determine 
autophagy characteristics in CAFs compared to NFs. We also assessed the role of HNSCC in 
CAF autophagy induction. Finally, given the dearth of current studies of autophagy inhibition in 
HNSCC, we assessed the utility of autophagy inhibitors in preclinical models. Our findings 
indicate a fascinating tumor-stroma symbiotic relationship centered around what is typically 






























Cells and Reagents 
HNSCC and tonsil or uvulopalatoplasty explants from cancer-free patients were collected 
with written consent from patients under the auspices of the University of Kansas Medical 
Center Biospecimen Repository Core Facility. All protocols for collection and use were 
approved by the Human Subject Committee at the University of Kansas Medical Center. Primary 
fibroblast explants were established using our previously described protocol (Wheeler et al., 
2014), and all fibroblast lines used were cultured for no more than 12 passages. In all 
experiments, results presented are from fibroblasts derived from a minimum of 2 patient 
explants. 
Well characterized HNSCC cell lines (UM-SCC-1 (a gift from Dr. Tom Carey, 
University of Michigan), OSC19, and HN5 (a gift from Dr. Jeff Myers, MD Anderson)), were 
used in this study (Lin et al., 2007). Established cell lines were authenticated by STR profiling at 
Johns Hopkins in 2015 using the Promega Geneprint 10 kit and analyzed using Genemapper v4.0 
software. All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Corning, 
Corning, NY) with 10% heat-inactivated FBS (Sigma-Aldrich, St. Louis, MO) without 
antibiotics. Cells were incubated at 37oC in the presence of 5% CO2.  
Chloroquine diphosphate salt, 4-nitroquinoline N-oxide (4-NQO), IL-6, IL-8 and bFGF 
were obtained from Sigma-Aldrich. SAR405 was obtained through APExBIO (Houston, TX). 
Cisplatin was obtained from Fresenius Kabi (Lake Zurich, IL).  
Antibodies used: LC3 A/B (#12741), Beclin-1 (#4122), phospho-p70 S6K (Thr389) 
(#9205), Stat3 (#9139), phospho-Stat3 (Tyr705) (#9145) from Cell Signaling (Danvers, MA); β-
tubulin from Sigma-Aldrich; p62 (SQSTM1, M01) from Abnova (Taipei, Taiwan); Vimentin 





(6217), and secondary anti-rabbit IgG Dylight 680 (#35568), anti-rabbit IgG Dylight 488 
(#35553), and anti-mouse IgG Dylight 800 (#35521) from ThermoFisher (Waltham, MA). 
Hoescht 33342 was used as a nuclear counter stain (ThermoFisher).  
Primer sequences used: mTOR (F: GGCCGACTCAGTAGCAT; R: 
CGGGCACTCTGCTCTTT); SOX2 (F: ACGGAGCTGAAGCCGCC; R: 
CTTGACGCGGTCCGGGCT); β-ACTIN (F: AGGGGCCGGACTCGTCATACT; R: 
GGCGGCACCACCATGTACCCT), all obtained from ThermoFisher.  
Control (#44236), siBECN1 (#29797), and siFGF-2 (#39446) siRNA was obtained from 
Santa Cruz Biotechnology. 
Electron Microscopy 
Tissues were processed at the KUMC Electron Microscopy research lab facility. Tissue 
samples were fixed in 2.5% glutaraldehyde in 0.1M cacodylate buffer, and postfixed in 1.5% 
osmium tetroxide. Samples were embedded in resin-propylene oxide and allowed to cure. 
Tissues were sectioned using a diatome diamond knife on a Leica UC-7 ultra microtome at 80 
nm thickness. Sections were collected on 200 mesh copper grids, and samples imaged using a 
J.E.O.L. JEM-1400 transmission electron microscope at 100KV.  
Immunoblotting 
Whole-cell lysates were extracted using RIPA lysis buffer and a mixture of protease and 
phosphatase inhibitors (Minitab, Roche). Lysates were sonicated on ice, debris removed by 
centrifugation, and supernatants stored at -80 oC. Sodium dodecyl sulfate-polyacrylamide 12% 
gels were used to separate proteins, and proteins were transferred to nitrocellulose membranes. 
Membranes were blocked with Odyssey blocking buffer (Li-Cor) in a 1:1 mixture with PBS 1% 





Primary antibodies were detected using DyLight conjugated secondary antibodies. Protein bands 
were detected using Li-Cor odyssey protein imaging system and quantified using ImageJ 
software (v. 1.50i). 
Immunofluorescent Imaging 
Cells were plated at a low confluence (10,000 cells per well) in 8-well chamber slides 
(Thermo Fisher). Methanol (70%) was used to fix cells. Triton-x (0.5%) in PBS was used as a 
permeabilization buffer. Cells were blocked with a 2% Bovine Serum Albumin (BSA) solution. 
For paraffin sections, paraffin was removed by xylene, and sections were rehydrated by ethanol 
titration. Antigen was retrieved using sodium citrate solution. Both cells and tissue sections were 
then incubated overnight in primary antibody (1:100 concentration in 2% BSA) at 4 oC. Dylight 
(488-anti rabbit; 550-anti-mouse) conjugated secondary antibodies were used, and Hoescht 
staining following manufacturer’s instructions was used for nuclear detection. Slides were 
mounted with coverslip in vectashield mounting media. Images were captured on a Nikon 
Eclipse TE2000 inverted microscope with a Photometrics Coolsnap HQ2 camera. LC3 puncta 
per cell of at least 30 cells in each experimental arm were identified by blinded observer at 20x 
magnification. 
Conditioned Media Collection 
CAFs (3x105 cells/well in 60mm dish) were plated in 10% FBS DMEM, and were treated 
with 20 µM Chloroquine for 6 h or vehicle control (H2O). Following drug treatment, cells were 
washed 2 times with serum free media, and then conditioned media was collected over 24 h in 
serum free DMEM. Following conditioned media collection, cell lysates were harvested for 
immunoblot analysis to confirm autophagy inhibition by assessing LC3 levels. Conditioned 





CAFs (3x105 cells/well in 60mm dish) were plated in 10% FBS DMEM, and were 
transfected with 100 nM siBeclin-1, siATG7 or siControl (Santa Cruz Biotechnology) containing 
lipofectamine-2000 (ThermoFisher) liposomes in Opti-MEM for 4 h. Media was changed to 10% 
FBS DMEM overnight, and conditioned media collection began the next day for 24 h in serum 
free DMEM. Following conditioned media collection, cell lysates were harvested for 
immunoblot analysis to confirm siBECN knockdown. Conditioned media was clarified by 
centrifugation and stored for no more than 2 weeks at 4 oC. 
Proliferation 
HNSCC cells were seeded in triplicate (2000 cells/well, 96-well plate). After cells had 
adhered, various experimental conditions were applied for 72 h duration. Cell viability was 
assessed using CyQuant proliferation kit (Life Technologies) according to manufacturer’s 
instructions. For irradiation experiments, plates were exposed to gamma radiation (J.L. Shepherd 
and Associates Mark I Model 68A cesium-137 source irradiator; dose rate = 2.9 Gy/min). 
Invasion & Migration  
Cell invasion and migration was assessed using the transwell Boyden chamber system. 
HNSCC cells were seeded in 8 µm pore inserts for migration. For invasion, a layer of diluted (2 
mg/mL) growth factor-reduced Matrigel (Corning) in DMEM was placed in the insert. HNSCC 
cells in serum-free media were seeded onto Matrigel. The inserts were placed in triplicate 
holding-wells containing treatment conditions for 24 h. Cells were also plated in experimental 
conditions in parallel to assess viability using CyQuant. The number of cells that moved to other 
side of membrane was counted after fixation and staining with Hema3 Kit (Fisher). The number 






Cytokine array (C5) was obtained from RayBiotech (Norcross, GA) and conditioned 
media from CAFs was analyzed following the manufacturer’s instructions.  
PCR 
HNSCC cells were CFSE-(ThermoFisher)-labeled following manufacturer’s protocol. 
CFSE-labeled HNSCC cells were co-cultured in a 1:1 ratio with unlabeled NFs for 72 h. Cells 
were harvested by trypsinization and FACS sorted using BD FACSAria IIIu. RNA was extracted 
from harvested cells using TRIzol reagent (Fisher) following the manufacturer’s instructions. 
RNA was subjected to DNAse digestion prior to cDNA preparation using the SuperScript First-
Strand Synthesis System (Invitrogen). PCR products were resolved on agarose gel and imaged. 
Densitometric analyses were performed with ImageJ (v1.50i). PCR array (PAHS-176ZD, 
Qiagen) was used to identify differences between NFs and co-cultured NFs, and read using 
CFX96 Real-Time System (Biorad, Hercules, California). 
Co-culture Proliferation Assay 
HNSCC cells were CFSE-(ThermoFisher)-labeled following manufacturer’s protocol. 
CFSE labeled HNSCC cells were co-cultured in 1:1 ratio with unlabeled CAFs for 72 h. Cells 
were harvested by trypsinization and labeled HNSCC cells were counted using Attune NxT Flow 
Cytometer (Life Technologies).  
In vivo Experiments 
All experiments were approved by the institutional review board at the University of 
Kansas Medical Center. To assess biomarker modulation by chloroquine, 100 µL of HNSCC 
(UM-SCC-1, 0.5x106) alone or admixed with CAFs (0.5x106) were injected into the right flank 





administered by oral gavage (162 mg/kg) for three days (Zou et al., 2013). Tissue was processed 
for electron microscopy.  
To assess autophagy inhibition in combination with cisplatin, 100 µL of admixed 
HNSCC (UM-SCC-1, 0.5x106) and CAFs (0.5x106) were injected into the right flank of athymic 
female mice. Mice (n=9/group) were treated with cisplatin (3 mg/kg i.p. 1x/week), chloroquine 
(162 mg/kg oral gavage, 5 days/week) or SAR405 (50 µL intratumoral injection of 10 µM 
SAR405 in PBS, concentration determined based on in vitro IC50, 5 days/week). Tumor 
diameters were measured by a blinded observer using Vernier calipers in two perpendicular 
dimensions as previously described (Wheeler et al., 2014). Tumors were excised and processed 
for electron microscopy.  
To assess progression of autophagy in developing tumors, 4-NQO (100 ppm in sterile 
drinking water ad libitum (X. H. Tang et al., 2004)) was administered for 16 weeks to C3H mice. 
Mice were then given sterile drinking water for 3 weeks, and tongues were excised. 
The Cancer Genome Atlas Data Analysis 
TCGA head and neck cancer (HNSC) cohort gene expression RNAseq data downloaded 
using UCSC Xena Browser (http://xena.ucsc.edu).  Expression levels of BECN1 or MAP1LC3B 
were designated as high or low in relation to median expression of gene-level transcription 
estimates (log2(x+1) transformed RSEM normalized count). This was matched to clinical 
survivorship data from TCGA HNSC Phenotype data downloaded from UCSC Xena.  
Statistical analysis 
Data are reported as mean ± standard error of mean (SEM). Non-parametric two-tailed 
Mann-Whitney U tests were used to assess significance in all experiments, and Kruskal Wallis 





employed to assess the level of significance in tumor volumes between treatment arms. For 
TCGA survivorship comparison, log rank (Mantel-Cox) test assessed differences between 
curves. All statistical calculations were performed on Graphpad Prism Software (version 6.03), 


























The most recent and pronounced clinical responses in HNSCC therapy act upon the 
microenvironment. For example, cetuximab, the EGFR monoclonal antibody, activates antibody 
dependent cell-mediated cytotoxicity. Additionally, nivolumab and pembrolizumab, PD-1 
targeted antibodies, activate an antitumoral T-cell response. Each of these therapies have made 
significant improvements in HNSCC outcomes by acting upon microenvironment cells, 
particularly immune cells; thereby, demonstrating the pronounced effects achieved by 
capitalizing on the tumor microenvironment. However, no current therapeutics attempt to modify 
the largest component of the HNSCC microenvironment, CAFs. Perhaps targeting 
communication between tumor and stroma may lead to novel therapeutics and better outcomes 
for HNSCC patients. 
Our poor understanding of the underlying biology of CAFs contributes to the dearth of 
therapeutics targeting this largely abundant cell population. Past studies from our lab and others 
document the pronounced tumor promoting effects of these cells. CAFs significantly contribute 
to HNSCC proliferation by secreting a variety of cytokines, notably HGF (Knowles et al., 2009). 
Additionally, CAFs likely lead the cancer away from the primary site (Gaggioli et al., 2007). 
This CAF-mediated invasion leads to distant metastasis of the carcinoma cells (Wheeler et al., 
2014). CAFs strongly promote cancer progression. However, despite broad documentation of 
CAFs enhancing HNSCC growth, secretory mechanisms contributing to this phenotype are 
unknown and not targeted.  
As such, we undertook studies to delineate how CAFs differ from NFs. We demonstrate 
pronounced structural differences between CAFs and NFs. Strikingly, CAFs, despite their rapid 





degradative pathway is highly upregulated in rapidly dividing, highly secretory CAFs. We 
characterize the surprising role for autophagy in cellular secretion, and provide evidence that 
CAF secretory autophagy enhances HNSCC progression. 
Results 
Given the broad secretory and tumor promoting differences between CAFs and NFs, we 
sought to understand the molecular mechanisms underlying the activated phenotype. As such, we 
undertook an ultrastructural investigation of CAFs compared to NFs. CAFs demonstrate a 
remarkably different architecture compared to NFs (Figure 4.1a, Appendix Figure 4.1b).  
At a whole cell view, NFs have a stereotypically normal appearance. A well-defined 
filament network, appropriate mitochondria, scant lysosomes and peroxisomes, and proper 
endoplasmic reticulum are easily observable. However, CAFs demonstrate a disrupted 
cytoplasm, littered with hundreds of vesicles. These vesicles take on both electron dense and 
electron lucid appearances, and cover the majority of cytoplasmic berth. They have a 
heterogeneous appearance, and vary in size. Electron dense, heterogeneous vesicles bounded by 
a single membrane typically characterize damaged lysosomes (Douglas Kelly, 1984). Whereas, 
normal lysosomes have an electron dense, and rather uniform appearance.  Many vesicles appear 
to contain smaller membrane bound vesicles, characteristic of multivesicular bodies, also termed 
secondary lysosomes (Douglas Kelly, 1984). Often, there are transitional forms of a lysosome 
and multivesicular body, but the function of these are unknown. Some vesicles appear to have 
both electron lucid and electron dense components within a single membrane. The electron dense 
component may be material indigestible by a lysosome, such as lipids, as lysosomes have a low 





things: 1) that CAFs have increased cellular digestion; or 2) there is a blockade of digestion that 
leads to an increased number of lysosomes.  
  
 
Figure 4.1a-CAFs Demonstrate Increased Autophagosomes than NFs 
(A) Electron microscopy exhibits highly vesicular architecture of CAFs with heterogeneous 
electron dense and electron poor organelles compared to NFs. Scale bars represent 0.5 µm. 
Graph depicts autophagosomes/fibroblast relative to NF expressed as percent. 
Autophagosomes counted in 36 fibroblasts from each group from at least four explants each 
from HNSCC or cancer-free subjects. Error bars represent ± SEM. 





























Intriguingly, many vesicles contain other cellular components. These are likely 
autophagosomes. Autophagosomes are characterized by (Figure 4.2): 
 1) Double Membrane Structure, 
 2) Cytoplasmic Cargo Enclosed, or in the process of engulfment by cup shaped 
structure, 
 3) Vesicular architecture, which differentiates from Golgi or endoplasmic reticulum, 
 4) A clear distinction from a mitochondria-which is characterized by an electron dense 
matrix, with a double membrane. The inner membrane of a mitochondria folds into the 
mitochondrial matrix in the form of many cristae. Although an autophagosome may 
engulf mitochondria, the inner membrane of the autophagosome does not form cristae, 







Figure 4.2 – Autophagosome Examples 
Autophagosomes (identified by arrowheads) were counted by blinded observer following these 
characteristics: 1) double membrane structure (Can be observed by arrow), 2) cytoplasmic 
cargo enclosed, 3) vesicular architecture to differentiate from Golgi or ER, and 4) clear 
distinction from mitochondria (asterisk). Images representative of two HNSCC tumor cells at 






By these criteria, CAFs demonstrate an abundance of autophagosomes, much greater than 
observable autophagosomes in NFs. The increased number of autophagosomes and lysosomes 
indicates that CAFs likely have increased autophagic flux compared to NFs. 
Autophagic flux is characterized by the packaging of intracellular cargo into an 
autophagosome. Typically, cargo is sequestered by an autophagy cargo receptor. Sequestosome 1 
(SQSTM1 or p62) is a paradigm cargo receptor. p62 binds ubiquitinated cargo, and traffics the 
material to the autophagosome. At the autophagosome, p62 binds LC3, which is cleaved and 
lipidated to the form LC3-II and is incorporated into the autophagosome membrane. LC3-II, the 
molecular tether of cargo to the autophagosome membrane, is the best marker of the 
autophagosome available. Increased autophagic flux yields increased LC3-II, but this is difficult 
to assess because LC3 and p62 are degraded in the lysosome. Thus, to accurately assess 
autophagy, a lysosomal enzyme inhibitor must be used to prevent the degradative step, allowing 
the autophagy intermediates to accumulate so that accurate assessment of total flux might be 
assessed. Chloroquine is a lysomotropic agent that neutralizes the acidic pH of the lysosome, 
thereby rendering the lysosomal proteases ineffective. This allows for accumulation of LC3, p62, 
and any cellular cargo. 
To confirm that the increased number of autophagosomes and lysosomes observed by 
TEM demonstrate increased flux, we assessed protein levels of LC3 and p62 by immunoblot 
(Figure 4.3). Chloroquine was used as a flux inhibitor. By immunoblot, CAFs have significantly 
increased LC3-II in chloroquine treated samples compared to NFs, indicating enhanced 
autophagic flux in CAFs. p62 was more pronounced in CAFs, but the differences between CAFs 





studies have not yet been conducted to characterize this. Thus, by immunoblot, we observe 
enhanced LC3-II in CAFs compared to NFs, which demonstrates enhanced autophagic flux. 
 
Figure 4.3-CAFs Demonstrate More LC3-II than NFs 
Representative immunoblot of CAFs compared with NFs with and without CQ (20 µM for 6 
h) for LC3 protein conversion and p62. Graph depicts percent cumulative density of LC3 levels 
in CQ treated lanes relative to NF, in 4 explants each of HNSCC or cancer-free subjects. LC3-
II levels were normalized to β-tubulin levels. Error bars represent ± SEM. 
 




















































Figure 4.4a-CAFs Demonstrate More LC3 Puncta than NFs 
Representative immunofluorescent of LC3 (green) puncta, Hoechst nuclear stain (blue), 
comparing NF with CAFs with and without CQ (80 µM for 2 h) (60x magnification). 
Cumulative results of LC3 puncta per cell counted by a blinded observer of at least 30 cells 
each of NFs and CAFs. The experiment was repeated 3 times using 3 explants each from 
HNSCC or cancer-free subjects. Error bars represent ± SEM.  





Immunofluorescence allows for the direct visualization of autophagosomes within a cell 
by targeting LC3, and examining puncta formation. As LC3 accumulates on the inner and outer 
membranes of an autophagosome, punctate accumulations of fluorescence signal correspond 
with autophagosomes. This offers an alternative method to characterize autophagosomes in both 
CAFs and NFs. By immunofluorescence, CAFs demonstrate significantly more LC3 puncta in 
CQ treated samples (Figure 4.4b, Appendix Figure 4.4b). This confirms enhanced autophagic 
flux within these cells. Thus, by TEM, immunoblot, and IF, CAFs have an increased number of 
autophagosomes and autophagic flux. 
As these are cultured cells, the question arose if the enhanced levels of autophagy could 
be due to the culture conditions, and might be a byproduct of the adherence of these cells to the 
plastic flask. Yet, if this was so, one would expect the same process to occur in NFs and CAFs as 
both these cell types are processed in the same way. These samples are obtained from a similar 
anatomic location from patients, digested using the same protocol, and passaged using the same 
technique. There are no differences between CAFs and NFs other than from which patient they 
were derived. Observing enhanced autophagy within CAFs is not likely a consequence of 
culturing the cells. 
Nevertheless, we analyzed histologic specimens to confirm the in vitro observations. One 
caveat occurs by the fact that a lysosomal inhibitor cannot be used on histologic specimens, so 
true autophagic flux cannot be observed. Thus, increased numbers of autophagosomes might 
occur because of either increased autophagy or defective degradation. Nonetheless, assessment 






To assess autophagy through the disease process, mice received drinking water 
containing the carcinogen, 4-nitroquinolone (4-NQO). 4-NQO induces DNA damage, and thus 
causes dysplasia on the tongue surfaces, which develops into squamous cell carcinoma. Tongues 
were assessed ex vivo for autophagosomes throughout the disease process (Figure 4.5). In normal 
tongue samples, scant LC3 puncta were observed in the stroma. Specimens with low grade 
intraepithelial lesions demonstrated LC3 puncta in the stromal fibroblasts alongside a subtle 
increase in LC3 puncta within the epithelium. As the disease progressed, LC3 puncta became 
strongly apparent within the stromal fibroblasts. Fibroblasts in invasive squamous cell carcinoma 
specimens demonstrated significant LC3 puncta compared to fibroblasts resident in normal 
tongue epithelium. In a murine model, these data corroborate the in vitro findings from patient-
derived CAFs and NFs. 
Additionally, in patient specimens, LC3 puncta increase as the disease progresses (Figure 
4.6). We assessed patient histology comparing normal tonsils and HNSCC specimens. In these 
specimens, vimentin, a marker of mesenchymal cells, delineated fibroblasts from squamous 
 
Figure 4.5 - LC3 Puncta Increases through Disease Progression 
Representative IF images of LC3 (green) puncta in 4-NQO induced HNSCC model progression 
from normal tongue epithelium, low grade squamous intraepithelial lesion (LSIL), high grade 
squamous intraepithelial lesion (HSIL), carcinoma in situ (CIS), and invasive squamous cell 
carcinoma (Invasive SCC) at 20x magnification, top, and 60x magnification, bottom. 
Arrowheads depict LC3 puncta accumulation. Blue is nuclear stain. White box indicates area 





cells. As vimentin would exist in all mesenchymal cells, and epithelial cells undergoing 
epithelial-to-mesenchymal transition also express vimentin, fibroblast morphology was also used 
to delineate fibroblasts from epithelial cells. In normal tonsillar specimens, fibroblasts had few 
LC3 puncta, and there was an overall low abundance of LC3 throughout the normal specimen. 
However, in HNSCC, there was robust LC3 puncta, and the fibroblasts demonstrated significant 
levels. Intriguingly, the increase in LC3 puncta occurs in both the fibroblasts and the epithelial 
cells, giving indication that LC3 puncta increase in both cell types through the disease process.  
 
These data point to the conclusion that fibroblasts increase autophagic flux through the 
disease process. TEM, IF, and immunoblot of patient derived CAFs demonstrate increased 
autophagic flux. IF of both a murine model and patient-histologic specimens also demonstrate 
 
Figure 4.6 – Increased LC3 Puncta in HNSCC CAFs compared to Tonsillar Fibroblasts 
Representative IF of LC3 (green) vimentin (red), or Hoescht (blue) in normal tonsil from cancer 
free patients and HNSCC. Graph depicts LC3 puncta/fibroblast (as determined by vimentin 
positivity in spindle shaped cells) of 12 fibroblasts from 10 each of cancer-free and HNSCC 





enhanced LC3 puncta in CAFs through the disease process. Surprisingly, CAFs proliferate much 
faster than NFs. Autophagy as a self-eating mechanism usually coincides with quiescent, non-
dividing cells. Yet, paradoxically, CAFs demonstrate enhanced autophagy. Perhaps autophagy 
has pleotropic roles within these cells. 
Autophagy dependent secretion provides a possible explanation for the role of enhanced 
autophagosomes within CAFs. Here, the autophagic cargo do not degrade within the lysosome, 
but are secreted. The exact mechanisms of this pathway are relatively understudied.  CAF 
autophagy dependent secretion may underlie many of the tumor-promoting roles observed by our 
lab and others.  
 To assess the role of autophagy dependent secretion in tumor progression, we inhibited 
autophagy within CAFs and collected the secreted factors in CAF conditioned media (CAF-CM). 
Beclin-1 is the upstream initiator of both degradative and secretory autophagy. Levels of Beclin-
1 correspond with autophagic flux. When Beclin-1 is inhibited, there is a significant decrease in 
autophagic flux. We collected Beclin-1 knockdown CAF-CM over 24 h, and assessed HNSCC 
proliferation, migration, and invasion. Substantiating previous reports, CAM-CM significantly 
increased HNSCC proliferation, migration, and invasion compared to serum-free basal media 
(SFM) (Figure 4.7). Intriguingly, Beclin-1 knockdown significantly attenuated CAM-CM 
contributions to proliferation, migration, and invasion. This indicates a role for Beclin-1 in 
cellular secretion. 
To better delineate if this phenomenon is unique to Beclin-1 or to autophagy as a whole, 
we inhibited additional components of this pathway. Atg7 is necessary for the enzymatic 
processing of LC3-I to LC3-II. Inhibition of Atg7 prevents proper formation of an 





to migration and invasion, corroborating the Beclin-1 findings (Figure 4.8). Both Beclin-1 and 
Atg7 modulating the ability of carcinoma cell lines to respond to conditioned media, indicates 
that autophagy likely has a secretory role within the CAFs. 
Lysosomal degradation provides the final step in the autophagic pathway. The only 
inhibitor clinically approved to target autophagy, chloroquine (CQ), acts upon the lysosome. 
Thus, to assess the relevance of targeting autophagy-dependent secretion in patients, we inhibited 
autophagy in CAFs with CQ. To mitigate any effects of extracellular CQ, cells were extensively 
 
Figure 4.7 – Beclin-1 knockdown in CAFs reduces CAF-induced HNSCC proliferation, 
migration and invasion 
(A) Representative immunoblot confirming Beclin-1 knockdown throughout CAF-CM 
collection. (B) Significant reduction observed in HNSCC migration, invasion, and proliferation 
with Beclin-1 knockdown CAF-CM (siBECN) compared to Control siRNA (siCon) or VC 
(Serum Free Media). Graph depicts combined results of at least three trials per experiments 
plated in triplicate using at least two different CAF patient samples. Migration and invasion 





washed following CQ incubation. LC3 levels following conditioned media collection 
demonstrate LC3-II accumulation in CQ treated cells compared to vehicle control treated cells 
(Figure 4.9A). This indicates CQ retained its effects through the 24 h CM collection period. 
Although, over the 24 h CM collection period, little change was observed in LC3-II levels 
 
Figure 4.8 - Atg7 knockdown in CAFs reduces CAF-induced HNSCC migration and 
invasion 
(A) Immunoblot confirms silencing of Atg7 (siATG7) by decreased LC3-II expression in CQ 
treated lane compared to control siRNA (siCon). (B) Significant reduction observed in HNSCC 
migration, invasion, in siATG7 compared to siCon. Graph depicts combined results of at least 
two trials per experiments plated in triplicate using two different CAF patient samples. 































Figure 4.9 – CQ inhibits CAF-induced HNSCC Proliferation, Migration, and Invasion 
(A) Representative immunoblot as validation of CQ autophagy inhibition throughout 
conditioned media (CM) collection. (B) Representative immunoblot of CAFs grown in 
complete media (10% FBS DMEM) or after 24 h of serum free media (mimicking conditioned 
media collection). CQ (20 µM for 6 h) was applied at the end of the treatment period. No 
significant differences between complete media and conditioned media LC3-II levels 
demonstrates no increase in autophagy. (C) CAFs pretreated with CQ were washed extensively 
to remove excess chloroquine and then CM was collected with and without CQ pre-treatment. 
HNSCC (OSC19) migration, invasion, and proliferation are significantly reduced in CAF 
autophagy inhibited CM. Graph depicts cumulative results from three independent experiments 
including triplicate treatments, using CAFs derived from two HNSCC patients.  Migration and 
invasion experiments were normalized to cell viability. Error bars represent ± SEM. (D) 5 min 
CQ treatment (20 µM) on CAFs did not significantly alter LC3-II conversion as assessed by 
immunoblot. (E) 5 min CQ treatment (20 µM) of CAFs prior to CM collection had no 




























































between CAFs in complete media or serum free media (Figure 4.9B). CQ-inhibited CAF-CM 
mitigated CAF contributions to HNSCC proliferation, migration, and invasion (Figure 4.9C). To 
control for any effects of lingering CQ following extensive washing, a 5-minute treatment of CQ 
was applied and then washed off at the same dose as the typical 6-hour treatment. This 5-minute 
treatment did not increase LC3-II levels after conditioned media collection, compared to the 
robust increase observed in the 6 h treated cells, indicating a productive washing protocol 
(Figure 4.9D). No significant differences in HNSCC migration occurred with 5-minute CQ 
treatment, indicating minimal contribution of lingering CQ from CAF-CM (Figure 4.9E). 
Additionally, similar reductions were observed in multiple HNSCC cell lines. Overall, CQ 
treated CAF-CM produced similar effects to Beclin-1 and Atg7 knockdown, indicating a role for 
CAF autophagy dependent secretion in HNSCC proliferation, migration and invasion. 
Of note, autophagy inhibition had little effect on CAF proliferation over the CM 
collection period. No differences in CAF number occur in autophagy-inhibited groups compared 
 
Figure 4.10 – CAF Cytokines Secreted in 
Beclin-1 Dependent Manner 
Relative density of top 4 cytokines recognized 
on cytokine array of CAF-CM with Beclin-1 






to vehicle treated samples. This reflects the high IC50 dose required of chloroquine to inhibit 
CAF proliferation. It is additionally important to note that CM collected under serum-free 
conditions may upregulate autophagic flux slightly. These findings substantiate the concept that 
CAF autophagy promulgates a secretory profile that enhances tumor progression. 
CAF autophagy modulates a secretory phenotype responsible for HNSCC proliferation, 
migration and invasion. To understand which factors secreted by CAFs modify these HNSCC 
factors, we assessed Beclin-1 knockdown CM using a cytokine array. This array identified IL-8, 
IL-6, GRO, and LIF as the most pronounced factors secreted from CAFs (Figure 4.10). CAFs 
demonstrate significant reductions in IL-8, IL-6, and a plethora of other factors, under Beclin-1 
inhibition.  The findings of IL-8 and IL-6 reductions were quite intriguing because of past reports 
linking these to HNSCC progression. If these were responsible for the differences observed in 
HNSCC proliferation, migration, and invasion, reconstitution of these in CAF-CM would restore 
the reduction observed under autophagy knockdown.  
Therefore, we assessed HNSCC migration following autophagy inhibition with and 
without IL-6 and IL-8. Reconstitution of these factors restored HNSCC migration to VC, control 
siRNA treated CAF-CM levels (Figure 4.11). This affirms the concept that these mediate, at least 
in part, the differences observed under CAF autophagy inhibition. Of note, the concentrations 
used of IL-6 and IL-8 correspond with reputable past reports, even though they are greater than 
what was observed in the ELISA. Nevertheless, the restored migration indicates the role of these 
factors in HNSCC migration, and the cytokine array and ELISA indicate the mitigation of these 









CAFs inarguably contribute to HNSCC disease progression; however, the underlying 
biological processes involved are poorly understood. We undertook investigation to discover 
what processes account for such promotion of disease by this microenvironmental cell type. Our 
results demonstrate pronounced activation of autophagy in CAFs compared to NFs. Data 
supporting this interpretation come from 21 combined patient samples of both CAFs and NFs 
across four experimental methods, giving strong validation to this conclusion. Additionally, the 
4-NQO murine model supports the concept that fibroblasts have enhanced autophagy through 
disease progression. This is the first observation of enhanced fibroblast autophagy from primary 
CAFs-derived from patient stroma, and corroborates recent observations of breast cancer cells 
 
Figure 4.11 – Reconstitution of IL-6 and IL-8 Restore Autophagy 
Inhibition’s Effects on CAF-induced HNSCC Migration 
Reconstitution of HNSCC (UM-SCC-1) migration in Beclin-1 knockdown 
CAF-CM with recombinant IL-6 (10 ng/mL) and IL-8 (80 ng/mL); data 






inducing autophagy in skin fibroblasts, and a Drosophila melanogaster tumor model where 
microenvironmental autophagy was observed (Katheder et al., 2017b; U. E. Martinez-
Outschoorn et al., 2010).  
While autophagy is conventionally a degradation pathway, recent reports of a role for 
autophagy in unconventional cellular secretion (Ponpuak et al., 2015) prompted us to investigate 
the role for CAF autophagy in secreting tumor-promoting factors. By collecting CAF 
conditioned media under autophagy inhibition through both upstream knockdown of Beclin-1, 
Atg7 and downstream lysosomal inhibition using chloroquine, we observed significant 
phenotypic differences in cancer progression in vitro. This indicated CAF autophagy modulates 
secreted factors important for tumor progression. Using a cytokine array, we identified IL-6 and 
IL-8 as being autophagy modulated in their secretion, consistent with previous observations of 
autophagy controlled secretion of these factors in other systems. IL-6 and IL-8 are elevated 
systemically in patients with HNSCC (Z. Chen et al., 1999), have been associated with resistance 
to targeted therapy (Fletcher et al., 2013), and are known to be secreted from stromal fibroblasts 
found in a number of cancer types (Nagasaki et al., 2014). This is the first report linking CAF 
tumor-promoting cytokine secretion with autophagy. Interestingly, IL-6, and IL-8 are among a 
plethora of factors associated with the senescence associated secretory phenotype (Coppe et al., 
2008). We observed that primary CAF lines demonstrate rapid proliferation despite autophagy. 
Our data also demonstrate that knockdown of Beclin-1 mitigated secretory autophagy and 
consequently reduced the levels of IL-6 and IL-8 in CAFs. Thus, reduced IL-6 and IL-8 secretion 
on inhibition of autophagy coupled with the rapid proliferation of these fibroblasts leads us to the 
conclusion that this is not a replication induced senescent phenomenon.  Recent reports indicate 





cancer (Sousa et al., 2016). Our data corroborate this finding and unveil a role for tumor 
microenvironment autophagy in altering secreted factors.  
Intriguingly, autophagy dependent secretion seems to account for some but not all of the 
CAF-mediated effects on HNSCC migration and invasion. CAF secreted factors robustly 
increase migration and invasion, but autophagy inhibition only attenuates this increase by 
approximately 50 and 75%, respectively. This indicates other mechanisms of secretion are still 
involved as migration and invasion do not return to SFM conditions. In regards to proliferation, 
CAF autophagy inhibition decreased proliferation to basal levels with no significant difference in 
respect to SFM. Perhaps a more pronounced increase in proliferation may allow for resolution if 
canonical secretory mechanisms are involved in factors promoting cancer proliferation. 
Nevertheless, all of these techniques at assessing HNSCC progression indicate a role for factors 
secreted in an autophagy dependent manner. 
Also of interest is the similarity of results obtained from CQ treated groups and RNA 
knockdown groups. Each method acted upon different stages of the autophagy pathway, Beclin-1 
at the most upstream, Atg7 at a more intermediate step, and CQ at the degradative lysosome. 
Intriguingly, the role for the lysosome in secretory autophagy is unknown. The mechanism of 
secretory autophagy is poorly defined, and only investigated in light of IL-1β as the secretory 
cargo (Kimura et al., 2017). In IL-1β secretion, the lysosome is bypassed, and the secretory 
autophagosome is directed to the cell membrane. Yet, in other instances, lysosomal inhibitors, 
such as Bafilomycin A1, prevent IL-1β secretion (Dupont et al., 2011). Additionally, NK cells 
and osteoclasts rely on secretory lysosomes to expel cytotoxic cargo, indicating a putative role 





similar results independent of lysosomal function, indicating the secretory mechanism we 
observe likely depends on the lysosome.  
A weakness of the current work is a lack of assessment of the secretome differences 
between Beclin-1 knockdown, Atg7 knockdown, and CQ treated CAFs. Additionally, future 
studies might better delineate the role for identified secretory autophagy mediators, such as 
TRIM16, and Sec22b (Kimura et al., 2017). Towards this end, the main cargo studied in other 
reports of secretory autophagy is IL-1β, which CAF-secreted levels were too low of a 
concentration to appreciate by cytokine array, and an RNA difference was not appreciated on 
RNA sequencing. Future studies specifically targeting secretory autophagy, rather than both 
degradative and secretory, may decrease adverse effects, as degradative autophagy is important 
for normal cellular homeostasis.  
Overall, CAFs demonstrate enhanced secretory autophagy compared to NFs. This 
significantly promotes HNSCC progression, and outlines a new avenue to direct therapy. 
Questions remain as to how HNSCC induces autophagy, and by what mechanism autophagic 
flux remains high in cultured CAFs. Additionally, although well studied in other cancers, the role 
of autophagy in HNSCC is under investigated. The patient histology specimens identify 
increased autophagosomes in squamous cells through disease progression; yet, few groups have 
assessed the role for autophagy inhibition in HNSCC. The results from CAFs indicate autophagy 



























A large portion of late stage HNSCC tumors consist of fibroblasts. A greater ratio of 
fibroblasts to HNSCC correlates with HNSCC tumor volume (Bae et al., 2014). This is 
supported by laboratory findings that identify CAFs to promote HNSCC proliferation, migration, 
and invasion (Wheeler et al., 2014). Previous investigations into CAF-mediated HNSCC 
progression from our lab attribute much of this finding to CAF-secreted HGF. HNSCC does not 
secrete HGF, however, it is instead secreted by the tumor microenvironment. CAFs secrete HGF, 
which facilitates HNSCC progression (Knowles et al., 2009; Wheeler et al., 2014). However, 
HGF inhibition only partially decreases CAF-induced HNSCC proliferation, migration, and 
invasions. This demonstrates there must be other factors involved in CAF-mediated HNSCC 
progression. 
The underlying secretory pathways mediating CAF-induced HNSCC progression are not 
well described. We demonstrate the role of autophagy-dependent secretion in mediating a large 
portion of CAF-induced HNSCC progression. Our previous results indicate that CAF-induced 
HNSCC proliferation, migration, and invasion are attenuated with CAF autophagy inhibition. 
HNSCC seems to regulate CAF autophagy, as CAFs have significantly greater autophagic flux 
than NFs. Yet, mechanisms by which autophagy induction occur in CAFs are unknown. 
HNSCC symbiotically communicates with CAFs. HNSCC induces adaptation of NFs to 
CAFs. This occurs through a plethora of HNSCC secreted factors, which facilitate CAF 
adaptation. The best studied of these fibroblast activating factors is TGF-β (Kellermann et al.). 
TGF-β induces the myofibroblast phenotype, and blockade of this factor inhibits fibroblast 
activation as assessed by α-SMA. Although the role of TGF-β in inducing α-SMA is well 





induces autophagy (Kiyono et al., 2009). Yet, in fibrotic conditions, TGF-β limits autophagy 
(Patel et al., 2012). This dichotomy indicates other factors within the HNSCC microenvironment 
likely have a greater influence on the induction of autophagy in CAFs we observed in Chapter 
IV. Beyond TGF-β, many HNSCC factors contribute to fibroblast activation. For example, the 
fibroblast growth factor family retains its namesake by increasing fibroblast growth. 
The FGF family consists of many soluble signaling ligands that bind to receptor tyrosine 
kinases (Ornitz & Itoh, 2015). Of these ligands, the FGF1 subfamily, consisting of acidic FGF 
and basic FGF (bFGF or FGF2) are the most well studied, with bFGF being the first FGF 
identified (Gospodarowicz, 1975). In HNSCC, bFGF is of interest as it binds FGFR2 expressed 
on the HNSCC cells in an autocrine signaling loop to cause disease progression (Marshall et al., 
2011). The role for bFGF in modulating the surrounding stromal fibroblasts has been a focus of 
active study by our lab.  
The induction of autophagy may arise from secreted factors such as TGF-β or bFGF, but 
may also come from other autophagy inducing stimuli. Autophagy induction focuses around two 
common themes – nutrient starvation and reactive oxygen species (ROS). Nutrient sensors have 
the most upstream effect on autophagy. mTOR recognizes amino acid conditions within the cell 
and serves as the molecular “brakes” on autophagy by means of inhibiting ULK1 activity 
(Sancak et al., 2008). AMPK responds to levels of glucose by assessing the ratio of AMP/ATP, 
and serves to activate ULK1 activity (J. Kim et al., 2011). Therefore, in conditions of low amino 
acids or low glucose, these two molecular mediators activate an ULK1 facilitated signaling 
cascade to promote autophagic flux. Beyond nutrient sensors, ROS serve as the other key 
autophagy inducers. Data supporting ROS induction of autophagy arise from studies on radiation 





(Chaurasia, Bhatt, Das, Dwarakanath, & Sharma, 2016). Although radiation has the capacity to 
ionize any molecule within the cell, the autophagy mediating effects are attributed to ROS 
(Scherz-Shouval et al., 2007). Exact molecular mechanisms of autophagy induction by ROS are 
unclear. ROS induce the activation of Atg4 (Scherz-Shouval et al., 2007); yet, this is not 
typically understood as a key upstream event in autophagy. Perhaps the widespread protein 
damage is sensed, and autophagic degradation is initiated by a yet unknown mechanism. A 
limitation in understanding ROS biology is that ROS are by nature short-lived molecules, and 
direct assessment of their role in autophagy induction is difficult to establish. Nevertheless, the 
role for ROS in inducing autophagy, even despite a murky mechanism, is well accepted. Thus, 
there may be a role for nutrient starvation and ROS in the microenvironment to induce CAF 
autophagy alongside a secreted factor.   
The HNSCC microenvironment consists of both ROS and a low abundance of nutrients. 
The rapidly growing tumor quickly depletes the nutrient supply, and thus may contribute to 
autophagy induction in CAFs. Additionally, damaged mitochondria within the HNSCC cells 
produce an abundance of ROS that exist both intracellularly and in the extracellular space 
(Schaaf et al., 2013). Beyond this, the dysregulated phenotype of HNSCC cells produces an 
abundance of hydrogen peroxide into the microenvironment and this likely contributes to CAF 
autophagy induction. Additionally, cancer cells secrete a number of factors, but the association 
of these factors with autophagy induction is largely unknown. 
Beyond head and neck cancer, investigations in other cancer models demonstrate the 
induction of fibroblast autophagy by cancer cells. The first report of this arose from the 
investigation of human foreskin fibroblast co-cultured with breast cancer cells (Ubaldo E. 





induced oxidative damage within co-cultured fibroblasts. This led to increased autophagy 
alongside a decrease in caveolin-1 expression. The role of autophagy induction in mediating 
breast cancer progression was not followed-up with by this or other groups. Recently, a mutant 
Ras Drosophila model also demonstrated pronounced microenvironment autophagy (Katheder et 
al., 2017a). This group attributed autophagy induction to STAT signaling within the 
microenvironment, which lead to ROS activation and stromal autophagy. Microenvironmental 
autophagy produced amino acids readily available for tumor growth. The ability of other cancer 
types to induce microenvironmental autophagy demonstrates the importance of understanding 
the underlying molecular mechanisms.  
Thus, we undertook studies to understand the molecular mediators of autophagy 
induction in CAFs. We hypothesized HNSCC induce CAF autophagy through secreted factors. 
We observed HNSCC-secreted bFGF initiated a remarkable signaling cascade which led to 
pronounced autophagy within stromal CAFs. Factors secreted in an autophagy dependent manner 
fed-forward and potentiated autophagy-induction. This establishes both a HNSCC mediated and 
CAF potentiated mechanism for autophagy induction in stromal fibroblasts, which is critical for 
CAF-mediated HNSCC progression. 
Results 
To begin to understand the molecular mediators of fibroblast autophagy, we co-cultured 
NFs with HNSCC. NFs have a low basal level of autophagic flux, allowing for clear observation 
of autophagy induction. Cytokeratin 14, an epithelial cell marker found in basal cells and 
robustly expressed in squamous cell carcinoma, differentiates HNSCC from fibroblasts. Upon 
co-culture with HNSCC, NFs demonstrated a pronounced accumulation of LC3 puncta (Figure 





microenvironment supplies a strong influence on CAF autophagy, and we focused our studies on 
understanding the mechanisms between these cell types rather than other microenvironmental 
components. 
 
Intriguingly, the low density of cells plated in co-culture helps to elucidate potential 
drivers of autophagy. For example, HNSCC induced NF autophagy in neighboring cells, but 
physical contact was not observable between each of these cells types. This indicates a secreted 
factor within the media initiates autophagic flux rather than direct cell-to-cell contact. We 
maintained a constant number of cells between experimental groups, and there was an abundance 
of nutrients in the media. This, alongside the short 24 h timeframe at which these observations 
 
Figure 5.1a – HNSCC Induces LC3 Puncta in Fibroblasts 
Representative IF of NFs in a 1:1 co-culture with HNSCC (HN5) with and without CQ (80 µM 
for 2 h) with cytokeratin 14 HNSCC label (red), LC3 (green) and Hoescht (blue) nuclear stain 
(40x magnification). Graph depicts cumulative results of LC3 puncta per cell counted by a 
blinded observer of CQ treated wells in at least 20 cells per group, results cumulative of three 
experiments using two different NF patient samples and presented relative to NF. 





were made, indicates autophagic induction in NFs is not likely a result of nutrient deprivation. 
These observations point towards a secreted factor responsible for autophagy induction.  
In an effort to elucidate activated pathways in co-cultured NFs, we used a PCR 
microarray to compare NFs in a homogenous culture and NFs derived from a HNSCC-NF 
culture (Figure 5.2). SOX2 demonstrated the greatest change between co-cultured NFs and NFs 
alone, with a robust increase in SOX2 in co-cultured NFs. SOX2 is well-known for its 
involvement in stem-cell maintenance, and as one of the four Yamanaka transcription factors 
mediating induction of pluripotent stem cells from fibroblasts (Takahashi & Yamanaka). 
Intriguingly, in these induced pluripotent stem (iPS) cells, autophagy is required to induce 
pluripotency (S. Wang et al., 2013). 
 
 
Figure 5.2 – Differentially Expressed Factors in NFs co-cultured with HNSCC 
PCR microarray of NF compared to NF sorted from co-culture with CFSE labeled HNSCC 
(HN5) for 72 h. Heat map represents fold change (red high, green low), and table describes 





SOX2 mediates the transient induction of autophagy in iPS cells (S. Wang et al., 2013). 
Ectopic expression of SOX2 leads to a dramatic increase in autophagy in mouse embryonic 
fibroblasts (MEFs). This coincided with a marked decrease in mTOR mRNA expression, 
indicating SOX2 transcriptionally repressed mTOR. SOX2 mediated mTOR repression lead to 
increased autophagic flux, as mTOR inhibits autophagy (S. Wang et al., 2013). Of note, Atg 
mRNA expression levels did not change despite an enhanced autophagic flux in iPS cells. SOX2 
induction may be key to autophagy induction in co-cultured NFs. 
Induction of SOX2 may occur through a variety of different stimuli. This includes Wnt 
signaling, hedgehog signaling, and PI3K signaling, all of which lead to increased SOX2 levels 
(Weina & Utikal, 2014). Of particular interest is the involvement of FGFR2 in SOX2 induction 
(Mansukhani, Ambrosetti, Holmes, Cornivelli, & Basilico, 2005). Not only is FGFR2 robustly 
expressed in the fibroblast compartment of HNSCC, it is highly upregulated in our PCR based 
array of co-cultured NFs compared to NFs alone (Figure 5.2). We hypothesized FGFR signaling 
is responsible for the increase in SOX2 observed in co-cultured NFs. 
Fibroblast growth factors are the ligand for FGFR2 and bFGF is highly expressed in the 
tumor microenvironment. Results from our lab indicate a role for bFGF in the induction of CAF 
proliferation and migration. This lead us to assess the role bFGF may have in activating 
fibroblasts. However, in regards to autophagy, bFGF reduces autophagy in other systems, such 
as myocardiocytes (Z.-G. Wang et al., 2015) and neuronal cells (H. Y. Zhang et al., 2013). 
Nevertheless, the strong induction of FGFR2 in our co-culture system, and the activation of 
CAFs by bFGF observed by other studies within our lab, led us to hypothesize bFGF induces 








Figure 5.3 – Fibroblast STAT3 and LC3-II 
dependent on FGFR 
Representative immunoblot of NF treated with 
HNSCC-conditioned media (CM), with and without 
FGFR inhibitor AZD4547 (2 µM) for 24 h, and CQ 











Figure 5.4 – HNSCC Induces SOX2 and 
Decreases mTOR in Fibroblasts through an 
FGFR Dependent Manner 
Representative gel image of PCR products from NFs 
or NFs after sorting from co-culture with CFSE 
labeled HNSCC for 48 h with and without FGFR 
inhibitor AZD4547 (2 µM). Graph depicts 
densitometric analyses of mTOR or SOX2 PCR 
product analyses relative to β-actin and normalized 
to NF alone; co-cultured NFs were sorted from CFSE 
labeled HNSCC (HN5) co-culture after 72 h with and 







Therefore, we assessed a role for bFGF in inducing autophagy. bFGF serves as a ligand 
with high affinity for FGFR1 and FGFR2 (Ornitz & Itoh, 2015). AZD-4547 serves as a kinase 
inhibitor for these receptors (Gavine et al., 2012). Using HNSCC CM on NFs, AZD-4547 
reduced levels of phosphorylated STAT3, a downstream mediator of FGFR2 signaling, (Figure 
5.3). This reduction in STAT3 coincided with a decrease in LC3-II. This gives credence to the 
notion that FGFR mediates autophagy induction. 
STAT3 bridges the connection between FGFR and SOX2. STAT3 directly binds to 
activated FGFR, and is phosphorylated to mediate its downstream effects (Dudka, Sweet, & 
Heath, 2010). STAT3 then directly binds the promoter of SOX2 to activate enhanced 
transcription (Zhao et al., 2015). HNSCC induced a marked increase in NF SOX2 levels (Figure 
5.4). AZD-4547, a potent FGFR inhibitor, blocked the induction of SOX2. This implicates a role 





SOX2 transcriptionally represses mTOR (S. Wang et al., 2013). This leads to an 
activation of autophagy. Supporting this concept, co-cultured NFs have repressed levels of 
mTOR mRNA (Figure 5.4). The suppression is relieved with AZD-4547. This indicates a role 
for FGFR in mediating both SOX2 overexpression and mTOR repression in the HNSCC-NF co-
culture. 
 
Figure 5.5a – bFGF Induces LC3 Puncta, LC3-II Lipidation and Decreases mTOR 
Activity In NFs 
(A) Representative IF of NF with and without bFGF (100 ng/mL for 24 h) with CQ flux 
inhibition (80 µM for final 2 h of bFGF treatment), LC3 (green), Hoescht nuclear (blue) (40x 
magnification). Graph depicts cumulative results of LC3 puncta per cell counted by blinded 
observer of NF +/- bFGF + CQ in at least 20 cells per group, and results are cumulative of three 
experiments using two different NF patient samples. (B) Representative immunoblot of bFGF 
(100 ng/mL for 24 h) with and without CQ (20 µM for 6 h) treated NF of LC3 and phospho-
p70S6K (Thr389). 






As the ligand for FGFR, bFGF is likely to induce the signaling cascade observed. 
Exogenously added recombinant bFGF induces robust accumulation of autophagosomes in NFs 
 
Figure 5.6a – HNSCC bFGF Mediates NF LC3 Puncta Induction 
Representative IF of NF, or NF co-cultured with either control siRNA transfected HNSCC 
(HN5) (siCon) or bFGF siRNA transfected HNSCC (sibFGF) in a 1:1 ratio. CQ (80 µM for 2 
h) was used to inhibit flux. LC3 (green) and Hoescht (blue) are visualized at 20X magnification. 
Graph depicts cumulative results of LC3 puncta counted per cell in CQ treated wells of at least 
39 cells per group, and presented relative to NF alone. 
Additional low magnification images included in Appendix, Figure 5.6b 
 
 
Figure 5.7 – bFGF Increases Factors 
Implicated in Autophagy Dependent 
Secretion 
NF treated with bFGF (100 ng/mL) 
increased secretion of IL-6 or IL-8 in 
conditioned media as determined by ELISA. 





(Figure 5.5, Appendix Figure 5.5b). Additionally, recombinant bFGF induced an increase in 
LC3-II, and a decreased level of phosphorylated p70S6K, a surrogate marker for mTOR activity. 
This indicates bFGF diminishes mTOR function and increases NF autophagy. HNSCC secreted 
bFGF likely activates autophagic flux in surrounding fibroblasts. Thus, we silenced bFGF in 
HNSCC cells and then co-cultured with NFs. With bFGF silencing, HNSCC-mediated induction 
of LC3 puncta significantly reduced (Figure 5.6, Appendix Figure 5.6b). Thus, HNSCC secreted 
bFGF stimulates autophagic flux in NFs. 
We previously demonstrated that autophagy-dependent secretion led to an increase in IL-
6 and IL-8 from NFs. We hypothesized bFGF would increase secretion of IL-6 and IL-8 
alongside its autophagy-inducing effects in these cells. Recombinant bFGF induced a marked 
increase in IL-6 and IL-8 (Figure 5.7). This demonstrates bthat FGF, alongside inducing 
autophagic flux, also leads to enhanced secretion of IL-6 and IL-8. 
IL-6 has recently been implicated in autophagy induction of cancer cells in a mutant Ras 
drosophila model (Katheder et al., 2017a). Additionally, IL-6 has been shown to enhance 
autophagy in prostate cancer cells. IL-6 and IL-8 are well understood to be in high levels within 
the HNSCC microenvironment (Curry et al., 2014). We hypothesized IL-6 and IL-8 may also 
induce autophagy in NFs in an autocrine manner. In a co-culture model, IL-6 and IL-8 
neutralizing antibodies prevented HNSCC induction of LC3 puncta (Figure 5.8). Additionally, 
recombinant IL-6 and IL-8 induced significant accumulation of LC3 puncta in NFs. This was 





Neutralizing IL-6 and IL-8 mitigated HNSCC induced LC3 puncta in NF-HNSCC Co-culture 
(Figure 5.9). Therefore, IL-6 and IL-8 induce a feed-forward mechanism to increase autophagy 
in CAFs. 
These results indicate a mechanism for HNSCC induction of fibroblast autophagy 
dependent secretion. This occurs through bFGF activation of FGFR, which leads to 
phosphorylation of STAT3. STAT3 induces SOX2 levels, which act to transcriptionally repress 
mTOR. This repression is alleviated by a STAT3 inhibitor. mTOR inactivation leads to an 
increase in autophagic flux. This coincides with an increase in IL-6 and IL-8 secretion from 
fibroblasts. IL-6 and IL-8 feedback on the system to activate further, sustained autophagy in 
 
 
Figure 5.8 – IL-6 and IL-8 Induce LC3 Puncta and LC3 Lipidation in NFs 
(A) Representative IF of NF treated with vehicle control (water), IL-6 (10 ng/mL), or IL-8 (80 
ng/mL) for 24 h with and without CQ (80 µM for last 2 h of cytokine treatment) (20x 
magnification). (B) Graph depicts cumulative results of LC3 puncta per cell counted by a 
blinded observer of at least 30 cells per experimental arm in three separate experiments. Error 
bars represent ±SEM. (C&D) Representative immunoblot of NF treated with (C) IL-6 (10 
ng/mL), or (D) IL-8 (80 ng/mL) for 24 h with and without CQ (20 µM for last 6 h of treatment). 
(D&E) Representative immunoblot of NF treated with (D) IL-6 (10 ng/mL), or (E) IL-8 (80 





fibroblasts. This reveals a targetable signaling loop of FGFR activation of CAFs, which leads to 
enhanced autophagy and secretion of IL-6 and IL-8 (Figure 5.10). 
  
 
Figure 5.9 – Neutralizing IL-6 and IL-8 Mitigates HNSCC-Induced, NF LC3 Puncta 
Representative images of NF alone or co-cultured in 1:1 ratio with HNSCC (HN5) for 24 h 
with either VC (water) or neutralizing antibody to IL-6 (anti-IL-6) or IL-8 (anti-IL-8); CQ (80 
µM for 2 h) used to inhibit autophagic flux. LC3 (green), cytokeratin 14 (red), or Hoescht 
(blue). Graph depicts LC3 puncta per cell of at least 20 fibroblast cells (as determined by 








Figure 5.10 – CAF Autophagy Induction Mechanism 
Schematic representation of the mechanism of autophagy induction in CAFs by HNSCC that 






CAFs significantly contribute to HNSCC disease progression. The molecular 
mechanisms regarding the cross-communication between CAFs and HNSCC cancer cells are 
largely unknown. Our results indicate HNSCC cancer cells induce CAF autophagy, which 
facilitates tumor-promoting secreted factors. This signaling loop will be useful in future 
therapeutic interventions for HNSCC, and also is likely applicable to other diseases with high 
levels of autophagy. 
An important finding from these studies is the role of HNSCC in inducing autophagy. 
Although many diseases have either over-activated or diminished autophagy, the list of known 
autophagy inducers is relatively short. The current understanding revolves around cellular 
metabolic deficiency and ROS mediated damage. Our work characterizing a mechanism for 
mitogen activation of autophagy in microenvironment cells indicates future research 
opportunities to understand the role of secreted factors in autophagy induction.  We observed 
bFGF, IL-6 and IL-8 all to have a pro-autophagic role within the fibroblasts. While the interest in 
the current work is to diminish autophagy to limit disease progression, other diseases might 
benefit from insights in autophagy induction. For example, neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s disease are attributed to diminished autophagy. Perhaps the 
evidence supplied here might be useful for future studies in these and other diseases.  
Additionally, the role for ROS and metabolic competition in HNSCC-mediated 
Activation of CAF autophagy is not discounted. Clearly, these stimuli are widely present within 
the HNSCC microenvironment. Cancer cells produce a large amount of ROS due to their 
damaged mitochondria (Liou & Storz, 2010). Additionally, the rapidly growing tumor creates a 





but rather adds additional detail to other microenvironmental stimuli involved in supporting 
autophagy-dependent secretion in CAFs. 
Our results build upon recent evidence of SOX2 mediating an activation of autophagy (S. 
Wang et al., 2013). This occurred in MEFs, and was crucial step in the transition of MEFs to 
pluripotency. SOX2 is widely known as a stem-cell transcription factor. Surprisingly, autophagy 
is highly upregulated in stem-cells (Maycotte et al., 2015). Stem-cell autophagy upregulation is 
attributed to IL-6. The data presented support the concept of a transient stem-like phenotype in 
microenvironmental fibroblasts. Additional studies are needed to better define a stem-like 
phenotype and any associated functional consequences.  However, CAFs do not seem to 
differentiate in culture. Patient-derived CAFs always maintain a fibroblast architecture.  
The PCR based microarray identified other factors altered between NFs co-cultured with 
HNSCC and NFs alone. For example, PTCH1 was significantly upregulated. PTCH1 is a 
member of the hedgehog family. Histology demonstrates PTCH1 increases in HNSCC 
fibroblasts, whereas it is largely absent in normal tissue-associated fibroblasts (Ghosh et al., 
2012). In regards to autophagy, hedgehog signaling impairs autophagy in Drosophila (Jimenez-
Sanchez et al., 2012). However, despite an indication that PTCH1 is increased in our system, 
NFs clearly have increased autophagy in co-culture with HNSCC. In HNSCC, the role for 
PTCH1 in CAFs is unknown. Future studies might elucidate the importance of upregulation of 
this factor in surrounding fibroblasts. Additionally, MYCN, DKK1, and CD24 were significantly 
down-regulated in co-cultured fibroblasts. Each of these have been well-studied in regards to 
epithelial cells. However, no studies address the role for downregulation of these in HNSCC 






The role of bFGF in stimulating autophagy and IL-6 and IL-8 secretion from NFs 
indicates a role in inhibiting this factor in HNSCC therapy. HNSCC have overexpressed and 
amplified FGFR (Daniele, Corral, Molife, & de Bono, 2012).  Previously, a role for FGFR in 
autocrine signaling has been defined, but our results build on this to indicate an important role of 
FGF in the stroma. The pronounced results of FGFR signaling in cancer progression led to a 
number of current therapeutic trials in HNSCC and other solid tumors (Porta et al., 2017). 
Although these trials currently do not investigate autophagy, it will be quite interesting to assess 
autophagy modulation in the presence of FGFR inhibition in patients.  
Sustained activation of autophagy in cultured CAFs is of interest for future studies. CAFs 
demonstrate high basal autophagy despite being cultured in the absence of cancer cells for 10-12 
passages. This indicates a long-term, inheritable modification occurs. Perhaps the autocrine 
secretion of IL-6 and IL-8 are in a concentration adequate to sustain autophagy in culture. 
Additionally, evidence in other cell types indicates IL-6 can induce epigenetic modification by 
changing the localization of DNA methyltransferases (Hodge et al., 2007). However, our studies 
did not investigate epigenetic or genetic modifications in CAFs compared to NFs. Future studies 
should also investigate the effects of CAF-CM on NFs to see if HNSCC are essential. It is 
possible that autophagy induction could occur in an HNSCC-independent manner. 
Also of interest is the role of autophagy in bFGF secretion. bFGF is an unconventionally 
secreted peptide, without a secretion signal sequence. Evidence suggests it passes through the 
cell membrane, but a role for autophagy-dependent secretion has not been assessed. In our 
RNAseq analysis, we observed a significant reduction of bFGF mRNA following Beclin-1 





Overall, these results shed light on the activation of CAFs in the tumor 
microenvironment. bFGF initiates a signaling cascade, which leads to decreased transcription of 
mTOR. This repression of mTOR removes the molecular brakes on autophagy and stimulates an 
autophagy-dependent secretome. These results demonstrate the important role of HNSCC in 
modulating the tumor microenvironment. IL-6 and IL-8 also demonstrate the role CAFs have in 



























Autophagy has a complex role in cancer (White & DiPaola, 2009). In some cases, 
autophagy protects against tumors. For example, Beclin-1 heterozygosity leads to an increase in 
spontaneous tumors, particularly lung cancer, liver cancers, and lymphomas (Qu et al., 2003). 
Additionally, Atg5 and Atg7 deficiencies lead to increased liver tumors (Takamura et al., 2011). 
Thus, autophagy acts to prevent tumorigenesis. However, autophagy also promotes tumor 
progression in late stages tumors. Metabolic stress within the tumor would typically lead to 
apoptosis of the cells. However, autophagy acts to promote cell survival, and restricts cell-death. 
Targeting autophagy in this scenario would promote cell death. These dichotomous interactions 
of autophagy-on one hand preventing tumor progression, while on the other facilitating tumor 
survival-makes dissecting the interactions of autophagy in cancer quite perplexing. 
Our results indicate microenvironment autophagy contributes to HNSCC progression. 
The data previously demonstrated support a role for autophagy-dependent secretion in the tumor 
microenvironment. CAFs have significantly more autophagy than NFs, and this increase in 
autophagy coincides with the secretion of factors important for tumor progression. Other reports 
in different cancers support the idea of targeting an autophagic microenvironment (Katheder et 
al., 2017a). This gives credence to inhibiting autophagy in late stage tumors with a high degree 
of activated CAFs. 
Besides a role for autophagy in the microenvironment, HNSCC has increased autophagy 
within the cancer cells. Our data indicate a role for autophagy in the cancer cells themselves. For 
example, HNSCC widely expresses LC3 puncta in our IF studies of HNSCC compared to normal 
tonsil histology. Additionally, cell lines of HNSCC robustly express LC3 puncta. Other groups 





with high levels of LC3 puncta and p62 associate with a poor prognosis in oral cancer (J. L. Liu 
et al., 2014). Increased LC3 puncta associating with worse prognosis is documented in other 
HNSCC sub sites (J. Y. Tang et al., 2013). Despite these findings, investigations are lacking as to 
the therapeutic potential of autophagy inhibition in HNSCC.  
Other solid tumors upregulate autophagy (White & DiPaola, 2009). In these tumors, 
targeting autophagy appears to have a therapeutic potential. This was first demonstrated with 
autophagy inhibition using CQ in a murine lymphoma model. Mice given 60 mg/kg qd of CQ 
alone had significantly less tumor growth (Amaravadi et al., 2007). This provides evidence for 
autophagy as a single therapeutic. Current paradigms suggest cancer cells upregulate autophagy 
as a mechanism to degrade toxic products that develop within the damaged cellular system. This 
would include damaged organelles, missense proteins, and to control for immune system attacks, 
such as the destruction of granzyme through autophagy. As such, combination therapy of 
inhibiting two degradative systems within the cell, such as the lysosome and proteasome, would 
produce pronounced effects. Demonstrations in colon cancer highlight the potential for dual 
proteasome-autophagy inhibition (Ding et al., 2009). When misfolded protein degradation is 
inhibited, rapid cell death initiates. This demonstrates cancer cells require a high basal level of 
autophagy for survival. 
Many current therapeutics also induce autophagy. This is true of nearly all cytotoxic 
drugs where cancerous cells upregulate autophagy as a survival mechanism (Shen et al., 2011). 
Therefore, combination therapy targeting autophagy alongside current therapy demonstrates 
effectiveness in a variety of tumors. For example, autophagy inhibition using chloroquine 
potentiates the effects of 5-FU in colon cancer models (Sasaki et al., 2010). Also, autophagy 





correlation to HPV status (Xu et al., 2012). These studies demonstrate targeting autophagy 
alongside current therapeutics used for HNSCC would likely potentiate effects. 
Chloroquine (CQ) has been widely used to target autophagy. CQ has been prescribed for 
the treatment of malaria and rheumatoid arthritis for many years. It has a well accepted safety 
profile, and can be taken for many years when living in an endemic area of malaria, or with the 
chronic condition of rheumatoid arthritis. However, retinal toxicity occurs after taking CQ for 10 
years. This led to the development of hydroxychloroquine (HCQ), which has the same chemical 
structure but with the addition of just one hydroxyl group. HCQ and CQ have the same 
mechanism, but HCQ does not have retinal toxicity. To substantiate the broad safety profile, 
suicide attempts with hydroxychloroquine are ineffective (Gunja et al., 2009). This indicates that 
large doses of 20 g can be achieved, and have few adverse effects (Gunja et al., 2009). A phase I 
dose-escalation study in dogs demonstrates safety of combining HCQ with chemotherapy and 
provided evidence that this treatment had potential benefit with a 93% overall response rate. 
These studies demonstrate the relative safety of CQ administration, and potential utility in cancer 
therapy. 
With a well-tolerated drug, and multiple cancers harboring high levels of autophagy, 
clinical trials assessing autophagy inhibition in multiple cancers have begun. The first clinical 
trial assessed the role of CQ in glioblastoma (Briceno, Reyes, & Sotelo, 2003). In this study, the 
median survival difference was 33 months in the combined CQ/standard therapy group compared 
to 11 months in the standard therapy alone group. Although this study was small, with only 18 
patients, the robust response cannot be overlooked. This led to the need to further assess 





Current published studies have been primarily dose finding in nature. As such, these 
studies have been relatively small, with a focus on biomarkers useful for determining doses of 
autophagy needed to have an effect. The most investigated peripheral marker is peripheral blood 
mononuclear cells. Adequate levels of HCQ result in buildup of autophagic vacuoles within 
these cells. At low doses-600 mg qd-no effect on peripheral blood mononuclear cells is observed 
(Mahalingam et al., 2014). At high doses, such as 1200 mg qd, peripheral blood cells 
demonstrate a significant increase in autophagic vacuoles (Rangwala et al., 2014). This high dose 
associates with a strong antitumor response in melanoma patients (Rangwala et al., 2014). In 
these trials, direct assessment of autophagy inhibition within the tumor did not occur, leaving an 
open question as to if intratumoral doses reached an adequate level. Of note, in the dog study, 
HCQ reached adequate concentrations to inhibit autophagy intratumorally; yet, a 100-fold 
difference in HCQ levels intratumorally was observed compared to plasma levels (Barnard et al., 
2014). These preliminary studies indicate that the HCQ maximum tolerated dose (MTD) varied 
with the combined therapy. For example, Vorinostat, a histone deacetylase inhibitor, had a MTD 
of 400 mg qd (Mahalingam et al., 2014); whereas, the MTD with an mTOR inhibitor reached 
600 mg bd (Rangwala et al., 2014). Dose limiting toxicities in these trials were primarily fatigue 
and gastrointestinal toxicity.  
With an understanding of tolerated doses, additional trials investigated the antitumor 
utility of autophagy inhibition using CQ. Despite the pronounced effects observed in early 
glioblastoma trials, not all trials demonstrate pronounced results. In a glioblastoma phase II trial 
with more patients (n=76), and CQ delivered at 600 mg qd, no significant differences were 
observed in treatment groups (Rosenfeld et al., 2014). However, myelosuppression limited 





(Rosenfeld et al., 2014). In patients with metastatic pancreatic cancer, HCQ as a single therapy at 
either 400 or 600 mg qd did not have any significant improvement (Wolpin et al., 2014). 
However, also in this trial, patient peripheral lymphocytes had inconsistent inhibition of 
autophagy (Wolpin et al., 2014). Of patients who demonstrated a greater than 51% increase in 
LC3-II following treatment, there was a significant difference in overall survival in pancreatic 
adenocarcinoma (Boone et al., 2015). Although these results suppress the enthusiasm of 
autophagy inhibition, they also indicate future studies will need greater dosing of HCQ to inhibit 
autophagy fully.  
With this background, 51 studies are currently ongoing to investigate autophagy 
inhibition for cancer patients (Levy, Towers, & Thorburn, 2017). Yet, all of these studies are 
focused on CQ or HCQ as methods of inhibiting autophagy. The preclinical and clinical trials 
aforementioned indicate a response should be expected, albeit limited by the high required doses 
of CQ needed. There is a need to better delineate autophagy inhibition as a therapy by using new 
therapeutics. 
CQ’s mechanism of action limits effectiveness. CQ is a lysosomotropic agent, 
permeating the lysosome and then neutralizing the acidity. As a base, the process of protonation 
within the lysosome traps CQ within this organelle. Yet, this mechanism also means that in other 
acidic environments, like the tumor microenvironment, the acidic conditions limit the 
permeability of CQ. Additionally, CQ affects other cellular processes that have acidic conditions 
(Pellegrini et al., 2014). For example, endosomes acidify during intracellular transport. Similarly, 
the Golgi apparatus has acidic components, as do secretory vesicles, and perhaps even secretory 





autophagy with an acceptable safety profile, off-target, non-specific effects indicate that claiming 
CQ as solely an autophagy inhibitor is inaccurate.  
 
Other autophagy inhibitors suffer from this low degree of selectivity. Autophagy 
inhibitors cluster into two broad categories: proximal inhibitors which target upstream events 
involved in producing the core autophagic machinery, and late stage inhibitors which target the 
lysosome (Figure 6.1). Proximal inhibitors target the upstream kinases, ULK1 and Vps34. As 
Vps34 is a PI3K, most proximal inhibitors are PI3K inhibitors, but have many non-targeted 
effects as such. 3-methyladenine (3-MA), Wortmannin, and LY294002 compose the three 
primarily used inhibitors. 3-MA has the dual role in both suppressing autophagy in nutrient 
starvation conditions, as well as activating autophagy by suppressing Class I PI3K (Y. T. Wu et 
al., 2010). A high dose is required to obtain physiologic affects, upwards of 10 mM in in vitro 
assays (Y. Wu et al., 2013). This is great enough to affect other kinases, such as MAPK and c-
Jun. Wortmannin and LY294002 also suffer from targeting other PI3Ks (Sarkaria et al., 1998) 
(Vlahos, Matter, Hui, & Brown, 1994). Of these three, only wortmannin has a more specific 
 





IC50 for Vps34 than other PI3K (Benoit Pasquier, 2016). The lack of specificity of these kinase 
inhibitors has spurred investigation to better targeted agents. 
Vps34 is an attractive target for selective autophagy inhibition. Vps34 is necessary for 
autophagy to occur (Kihara et al., 2001). The only known Vps34 non-autophagy related function 
is the vesicular transport of endosomal vesicles (E. E. Johnson, Overmeyer, Gunning, & Maltese, 
2006). Binding partners of Vps34 seem to dictate its function towards autophagic or endosomal 
pathways. When Vps34 complexes with UVRAG, it functions as an endosomal mediator; but 
when it complexes with Beclin-1 and Vps15, it participates in the development of the 
autophagosome (Vanhaesebroeck, Guillermet-Guibert, Graupera, & Bilanges, 2010). Thus, 
investigations have sought to inhibit this target 
Two primary methods exist to modulate Vps34 activity: 1) hasten the degradation of this 
kinase, 2) inhibit the catalytic activity. Spautin-1 is the first Vps34 inhibitor, and acts to hasten 
the degradation. Derived from a parent compound targeted at phosphodiesterase 5 (PDE5) 
identified in an anti-autophagic screen, spautin-1 was designed to have decreased activity against 
PDE5, and enhanced anti-autophagic activity (Takase et al., 1994) (L. Zhang et al., 2007). It 
inhibits USP10 and USP13, two enzymes that deubiquitinate the Beclin-1 complex which leads 
to the degradation and depletion of autophagy (J. Liu et al., 2011). However, this is an indirect 
method of inhibiting autophagy, and likely, other functional consequences of inhibiting 
deubiquitinases exist. Two groups, Sanofi and Novartis, have recently developed inhibitors 
targeting the catalytic domain of Vps34. Novartis designed VPS34-IN1 and PIK-III, which have 
biochemical IC50s of 25 nM and 18 nM, respectively, and are highly selective for Vps34 
compared to other protein and lipid kinases (Bago et al., 2014; Dowdle et al., 2014). VPS34-IN1 





strong inhibition of autophagic flux at 10 µM. Sanofi designed SAR405, which is potent and 
selective for Vps34. No other kinases were affected at 1 µM, and at the concentration, SAR405 
demonstrated excellent inhibition of autophagic flux (Ronan et al., 2014). This lasted even 
during autophagy induction by mTOR inhibition and starvation (Ronan et al., 2014). After 
designing SAR405, other compounds were investigated to improve in vivo application. 
Compound 31 demonstrated inhibition of Vps34 in vivo, but no autophagic flux inhibition has 
been demonstrated (B. Pasquier et al., 2015). Thus far, SAR405 is the most potent inhibitor of 
autophagic flux available, and is the most specific for the autophagy pathway.  
A thorough discussion would be remiss without mentioning ULK1 and late-stage 
inhibitors. SiRNA screening demonstrates the important role of ULK in mediating autophagy 
(Chan, Kir, & Tooze, 2007). Three ULK inhibitors exist, Compound 6, MRT68921, and SBI-
0206965. However, these either have poor selectivity for ULK1 or have not been assessed in 
terms of autophagic flux inhibition (Petherick et al., 2015) (Egan et al., 2015). ULK inhibitors 
are newly made, and poorly selective. However, they may show promise in the future. Yet, 
current applications are limited by their off-target affects. Late inhibitors of autophagy act upon 
the lysosomal enzymes to prevent autophagosome degradation (Muller, Dennemarker, & 
Reinheckel, 2012). Pepstatin A and E64D act directly on lysosomal cathepsins. Other inhibitors 
target the acidic pH required for lysosomal enzyme function. Bafilomycin A1 blocks lysosomal 
proton transport, and therefore inhibits autophagic flux (Klionsky, Elazar, Seglen, & 
Rubinsztein, 2008). Additionally, the CQ derivative-Lys05 has recently been developed to have 
a 10-fold greater potency than CQ at raising the lysosomal pH, and demonstrated significant 





lysosome are still attenuated by Lys05. These ULK1 inhibitors and late stage inhibitors offer a 
foundation for future drug design, but at the current stage are not specific enough. 
With this in mind, autophagy inhibition as a therapy has not been investigated in 
HNSCC. Thus, there is clinical utility in understanding the role of the currently available 
therapeutic, CQ, as a therapy. Additionally, there are no reports of the potent and selective 
inhibitor of Vps34, SAR405, as a cancer therapeutic in any cancer types. Thus, we undertook 
investigation to assess the role of autophagy inhibition using both CQ and SAR405 in HNSCC as 
single agents and in combination with current therapy.  
Results 
Autophagy associates with poor clinical outcomes in HNSCC. Increased LC3 puncta 
associates with a poor prognosis, and multiple groups confirm this (J. L. Liu et al., 2014) (J. Y. 
Tang et al., 2013). However, LC3 studies have consisted of relatively small sample sizes. To 
 
Figure 6.2 – High Expression of Autophagy Initiator, BECN1, Correlates with Patient 
Survival 
(A) LC3 (MAP1LC3B) overexpression does not significantly correlate with survival. (B) 
Beclin-1 (BECN1) expression does correlate with survival. Data downloaded from TCGA 
HNSC cohort, and stratified by median RNA expression (RSEM). High expression was 
determined by primary tumor patient samples that had greater expression than median (Log2 





build on this, we assessed the TCGA database for autophagy associated transcripts in the HNSC 
RNAseq database. Surprisingly, MAP1LC3B, the gene encoding LC3, did not associate with 
survival. Increased transcripts of LC3 does not by itself increase autophagic flux (Figure 6.2). 
However, Beclin-1 expression is analogous to autophagic flux (X. H. Liang et al., 1999). In the 
TCGA cohort, patients with increased Beclin-1 had a significantly worse overall survival (Figure 
6.2). This, alongside other reports, indicates the therapeutic potential of targeting autophagy in 
HNSCC.  
 
Figure 6.3 – CQ Inhibits HNSCC Proliferation, Migration, and Invasion 
(A&B) CQ reduces HNSCC, (A) UM-SCC-1 and (B) HN5, proliferation with IC50=12.58 and 
11.51 µM over 72 h. (B&C) CQ mitigates HNSCC (UM-SCC-1) (B) migration and (C) 
invasion at IC50 concentration. Migration and Invasion normalized to cell viability, and graph 





With a clear indication for a role of autophagy in HNSCC, we sought to assess the 
therapeutic potential of autophagy inhibition using CQ. CQ inhibits HNSCC proliferation, albeit 
with a relatively high IC50 of approximately 12 µM (Figure 6.3). Inhibiting HNSCC with CQ 
also inhibited HNSCC migration and invasion (Figure 6.3). Therefore, as a stand-alone therapy, 
 
Figure 6.4 – CQ Potentiates the Effects of 
Current HNSCC Therapies in vitro 
(A) Combination of CQ (IC50) and Cisplatin (4 
µM) significantly reduces HNSCC (UM-SCC-
1) proliferation over 72 h. (B) Combination of 
CQ (IC50) and radiation (3 Gy) significantly 
reduces HNSCC proliferation over 72 hours. 
Graph depicts three experiments plated in 





CQ demonstrates potential at limiting HNSCC progression, but reaching effective doses might 
limit clinical use.  
The promising results of CQ used with cytotoxic therapies in other cancers prompted us 
to investigate the role of CQ in combination with HNSCC current therapies. Cisplatin supplies 
the therapeutic backbone of HNSCC chemotherapy. By combining IC50 doses of cisplatin and 
CQ, a potentiated antitumor response occurred, greater than either single agent did (Figure 6.4). 
Radiotherapy also serves as a major therapeutic modality for advanced disease. In combination 
with 3 Gy of radiation, CQ potentiated the effects of radiotherapy (Figure 6.4). These preclinical 
data suggest the therapeutic potential of autophagy inhibition in combination with current 
treatment regimens.  
Our previous results indicated a role for autophagy both in the tumor and in the CAFs. To 
better delineate the effects of autophagy inhibition in the tumor cells compared to autophagy 
inhibition in CAFs, we established a co-culture assay of both cell types by labeling HNSCC cells 
with CFSE. Following a 72 h co-culture, HNSCC proliferation was determined by flow 
cytometry of labeled cells. This allowed for individual assessment of CQ treatment, and/or 
Beclin-1 knockdown in CAFs. As observed with our previous proliferation study, CQ treatment 
of cancer cells alone significantly reduced HNSCC proliferation (Figure 6.5).  Addition of CAFs 
significantly increased HNSCC proliferation, which was ameliorated by both knockdown of 
Beclin-1 in CAFs and the use of CQ.  This further established the role of CAF autophagy in 








Figure 6.5 – Autophagy Inhibition Reduces CAF-Induced HNSCC Proliferation 
  CFSE labeled HNSCC (HN5) proliferation over 72 h co-cultured in 1:1 ratio with CAFs with 
and without pre-treatment of Beclin-1 siRNA knockdown, and with and without CQ (IC50) 
throughout 72-hour co-culture. Graph depicts results of two separate experiments using two 







Figure 6.6 – SAR405 Inhibits HNSCC Autophagy, Proliferation, and Potentiates 
Cisplatin 
(A&B) SAR405 reduces HNSCC, (A) UM-SCC-1, (B) HN5, proliferation with IC50=7.92 and 
8.54 µM over 72 h, graph depicts three experiments plated in triplicate. (C) CAF proliferation 
is not effected by SAR405 inhibition over 72 hour period. (D) Representative immunoblot of 
increasing doses of SAR405 with and without CQ flux inhibition (20 µM for 6 h). Experiment 
repeated twice. (E) Representative immunoblot of 1.0 µM SAR405 on CAF with and without 
CQ flux inhibition (20 µM for 6 h). Experiment repeated twice. (F) SAR405 (1µM) potentiates 
the effects of cisplatin (4 µM) to inhibit HNSCC (HN5) proliferation over 72 hours, graph 






With these studies, promising in vitro evidence suggests a role for CQ in HNSCC 
patients. However, due to the high dosing required, and the non-autophagic effects of inhibiting 
the lysosome, we sought a more specific autophagy inhibitor. SAR405 is the most selective and 
potent inhibitor of the autophagy pathway to date. Compared to HNSCC proliferation inhibition 
by CQ, SAR405 had a slightly improved IC50 of approximately 8 µM (Figure 6.6). However, the 
dose required to inhibit LC3-II was a significantly lower dose. SAR405 (1 µM) strongly 
inhibited autophagic flux in both HNSCC and CAFs (Figure 6.6). Beyond selectively inhibiting 
autophagy, SAR405 demonstrates pronounced results in combination with HNSCC standard of 
care (Figure 6.6). SAR405 potentiates the effects of cisplatin. This indicates the therapeutic 
potential of inhibiting autophagy in combination with HNSCC standard of care. 
Given the promising results observed in vitro, we sought to assess autophagy inhibition in 
murine models of HNSCC. The dosing of CQ varied in preclinical studies, so we conducted a 
 
Figure 6.7 – CQ Inhibits Intratumoral Autophagy, and CAFs increase HNSCC 
Autophagosomes 
Representative electron microscopy images of sections from CAF and HNSCC (UM-SCC-1) 
injected subcutaneously into nude male mice. CQ (162 µg/mL oral gavage) treatment 
significantly enhanced autophagosome accumulation. Autophagosomes per cell were counted 






pilot study of HNSCC alone or HNSCC and CAFs inoculated in a 1:1 admixture subcutaneously 
in athymic mice. The dose we used established robust accumulation of autophagosomes within 
HNSCC cells, demonstrating the effectiveness of autophagy inhibition in our study (Figure 6.7). 
Of surprising interest, when CAFs were co-inoculated with HNSCC, more autophagosomes were 
detected in the HNSCC cells. This demonstrates the role fibroblasts have in inducing increased 
autophagy in HNSCC.  
To assess autophagy inhibition in combination with current standard of care, cisplatin, 
HNSCC were inoculated in a 1:1 admixture subcutaneously in athymic mice. Mice were treated 
with autophagy inhibitors CQ or SAR405 and/or cisplatin. With the addition of autophagy 
inhibitor SAR405 to cisplatin therapy, there was a significant reduction in tumor volume when 
compared to SAR405 alone, cisplatin alone, or untreated mice (Figure 6.8). Chloroquine and 
cisplatin combination treatment reduced tumor volume, but the reduction was not as significant 
as the more specific inhibitor, SAR405. Additionally, by electron microscopy, we were able to 
observe the significant reduction in autophagosomes per cell due to SAR405 therapy. This 
indicates the use of targeted autophagy inhibition will potentiate the efficacy of current therapy. 
These results support the direction of autophagy inhibition in HNSCC therapy. Both CQ 
and SAR405 potentiated the effects of cisplatin. Our in vitro results demonstrate this potentiation 
would also occur with radiotherapy. Both radiotherapy and cytotoxic agents increase autophagy 
in other tumor types, and this likely occurs with our models. Finally, SAR405 demonstrated the 
most potent effects, indicating the need for clinical studies to focus on specific autophagy 










Figure 6.8 – Autophagy Inhibition Potentiates Cisplatin in HNSCC-CAF Xenograft 
Autophagy inhibition potentiates standard of care therapy. 1:1 admixture of CAF & HNSCC 
(UM-SCC-1) were injected subcutaneously in nude female mice. Mice were treated with 
cisplatin (3 mg/kg i.p. 1x/week), chloroquine (162 mg/kg oral gavage, 5 days/week) or SAR405 
(50 µL intratumoral injection of 10µM SAR405 in PBS) (n=9/group). Tumor volumes were 






Current understanding of the role for autophagy in HNSCC is lacking. Some prior 
histologic evidence supported the role of high autophagy correlating with worse disease; yet, 
other reports indicate the opposite. In our studies, we demonstrate a correlation between Beclin-1 
expression and worse prognosis. This association is ratified in preclinical models as autophagy 
inhibition inhibited HNSCC proliferation, migration, invasion, and in vivo tumor volume. 
Autophagy inhibition potentiated the effects of standard of care therapies for HNSCC. All of this 
supports tumor autophagy as a mechanism that drives tumor progression. 
The bulk of current evidence for autophagy inhibition uses the lysosomal inhibitor CQ. 
Although CQ has late stage effects on autophagic flux, autophagosomes still form and cargo is 
sequestered following CQ administration. This means autophagic flux is attenuated, but cargo 
destined for autophagy likely remain sequestered. This limits the effectiveness of this therapy 
strategy, and is evidenced by the insignificant results of CQ as a single agent in our CAF-
HNSCC murine model. However, the early stage inhibitor, SAR405, had a pronounced effect as 
a single agent, and the greatest effect as a combination component. Thus, future studies targeting 
autophagy must investigate using more specific inhibitors than CQ. 
Despite SAR405 having pronounced results in our hands, this is still a non-selective 
autophagy inhibitor. SAR405’s target, Vps34, assists in trafficking both the autophagosome and 
the endosome, and the selectivity depends on the associated members of the Vps34 complex. 
Perhaps future therapeutics will dissect the functionalities of this complex to limit autophagy 
while still allowing Vps34 to be involved in other processes. Overall, more specific inhibitors to 





Of interest in our findings, high doses of CQ and SAR405 limited HNSCC growth; 
however, CAF proliferation was largely unaffected. This indicates that although both the cancer 
cells and CAFs have significant levels of autophagic flux, autophagy is only required for 
HNSCC proliferation. Perhaps HNSCC tumors are addicted to autophagy. Autophagic addiction 
was proposed in breast cancer, where certain subtypes have a predilection for autophagy. 
Autophagy inhibition in these subtypes leads to an extraordinarily effective strategy (Maycotte et 
al., 2014). Additionally, Ras mutations, which are commonly associated with HNSCC, are 
associated with high autophagy, and a dependence on this pathway for survival (Guo et al., 2011; 
Perera et al., 2015). Whether the tumor is addicted to autophagy or not is overshadowed by 
autophagy inhibition attenuating tumor growth in multiple cell lines and in multiple models.   
One handicap of the current studies is the lack of autophagy inhibition in an 
immunocompetent host. Results that developed as this project was ongoing indicate the immune 
system relies on autophagy to mediate its effects. For example, although autophagy increases 
effectiveness of radiation in vitro, in some animal models of other tumor types, autophagy 
inhibition diminishes the immune response and these tumors grow more following radiotherapy 
(Ko et al., 2014). Additionally, one group suggests the role for secretory autophagy in mediating 
the release of ATP from dying tumor cells. Released ATP stimulates the immune system towards 
a rapid anti-tumor response (Michaud et al., 2011). However, despite these findings, autophagy 
inhibition limiting the immune response is controversial. No differences in T-cell responses 
following autophagy inhibition were observed in other tumor models (Starobinets et al., 2016). 
Additionally, inhibiting autophagy potentiated the effects of natural killer cells and IL-2 therapy 
(Baginska et al., 2013) (X. Liang et al., 2012). Therefore, future studies should assess the role of 





Additionally, there is a need to delineate the specific effects of autophagy in each 
microenvironment compartment. For example, we have observed both HNSCC autophagy and 
CAF autophagy contribute to tumor progression, but we do not know which has the greater 
influence. I attempted three different trials of silencing Beclin-1 using short hairpin inhibition in 
CAFs, but this had no avail. CAFs did not grow due to technical limitations that prevented direct 
assessment of autophagy inhibition in a compartment specific manner.   
Nevertheless, autophagy within the cancer cells demonstrates a useful therapeutic target 
in HNSCC. Both single agent and combined therapy demonstrate the therapeutic potential of 
targeted autophagy inhibition. This builds upon our work of the usefulness in targeting CAF 
autophagy. Some open questions remain for future work, such as the role of autophagy in the 
immune response, and the effects of a more targeted autophagy inhibitor. Yet, using the most 
selective autophagy inhibitor in a robust preclinical model of CAF-HNSCC tumor xenografts, 
we demonstrate pronounced results in combination therapy with current treatment. Given the 

























Reciprocal communication between cancer cells and the tumor microenvironment 
sustains and enables cancer progression. For the past decade, the contribution of stromal cell 
secreted factors to the progression of cancer has been appreciated (Quail & Joyce, 2013), 
however the underlying secretory machinery involved remains enigmatic. We observe that CAFs 
in culture appear phenotypically different from NFs from the same anatomic location, displaying 
a highly vesicular architecture. This led us to question what fundamental biologic mechanisms 
account for the cancer-promoting secretory profile. In this study, we observe that primary 
patient-derived CAFs sustain an increased level of basal autophagy as compared to NFs from 
cancer-free patients. This is the first observation of enhanced fibroblast autophagy from primary 
CAFs-derived from patient stroma, and corroborates recent observations of breast cancer cells 
inducing autophagy in skin fibroblasts, and a Drosophila melanogaster tumor model where 
microenvironmental autophagy was observed (Katheder et al., 2017b; U. E. Martinez-
Outschoorn et al., 2010).  
We observed an increase in fibroblast autophagy on co-culture with HNSCC cells. The 
list of known physiologic autophagy inducers is short (Vakifahmetoglu-Norberg, Xia, & Yuan, 
2015), with amino acid/glucose starvation and reactive oxygen species being some of the only 
understood natural inducers. HNSCC metabolically outcompeting CAFs for extracellular 
nutrients may play a role in inducing CAF autophagy (Chang et al., 2015). However, assessment 
occurred in a short, 24 h timeframe in high glucose DMEM, which likely indicates this is not a 
starvation or nutrient depletion phenomenon. We identified IL-6, IL-8, and bFGF, known 
HNSCC-secreted factors, are all at least in part responsible for CAF autophagy. This 
corroborates recent findings in a Drosophila tumor model that IL-6 secretion from the tumor 





activates STAT3, induces the transcription of SOX2, which inhibits mTOR transcription (S. 
Wang et al., 2013). As mTOR represses autophagy (J. Kim et al., 2011), SOX2 inhibition of 
mTOR conferred increased autophagy in the fibroblasts in our system. The dynamics of CAF 
autophagy regulation are even more complex when taken into account our observation that 
autophagy promoting IL-6 and IL-8 are also secreted through autophagic machinery. 
There is extensive evidence in the literature demonstrating that both chemotherapeutic 
drugs and radiation promote cytoprotective autophagy in tumor cells (Sui et al., 2013). Despite 
multiple studies in a variety of cancer cell types, investigations into the therapeutic potential of 
autophagy inhibition in HNSCC is lacking (Sannigrahi, Singh, Sharma, Panda, & Khullar, 2015). 
Our results provide evidence for the first time of autophagy inhibition as having therapeutic 
potential in HNSCC. The largest limitations to autophagy treatment in clinical trials has been the 
high doses required of chloroquine, which may fail to achieve intratumoral concentrations 
sufficient to limit autophagy, and a lack of accepted methodology for monitoring autophagy in 
patients’ tumors to confirm successful inhibition (Poklepovic & Gewirtz, 2014). As such, a large 
body of research is investigating potential small molecule inhibitors of autophagy, and a few 
have been discovered (Solitro & MacKeigan, 2016). SAR405 is one such inhibitor that 
specifically targets PI3K class III, of which the only recognized member is Vps34, an upstream 
autophagy regulating kinase. We observed that low doses of SAR405 (1.0 µM or less) were 
sufficient to limit HNSCC and CAF autophagy in vitro. This may provide a feasible therapeutic 
alternative to chloroquine or hydroxychloroquine for clinical autophagy inhibition. The 
potentiated effects of HNSCC standard of care, cisplatin, with SAR405 in vivo were profound 






Autophagy Inhibition as a Therapeutic Strategy 
Our data demonstrate substantial improvement in treatment groups when an autophagy 
inhibitor is combined with current therapy. Additionally, many clinical trials give evidence to the 
safety and efficacy of CQ or HCQ in patients. Therefore, should autophagy inhibition progress as 
a therapy in HNSCC? 
Few arguments exist to refute this therapeutic strategy in advanced tumors. In some 
cases, autophagy can prevent cell death. This occurs when degradative autophagy removes 
inhibitors of apoptosis, such as Fap-1 (Fas-associated phosphatase 1) (Gump et al., 2014). 
Inhibiting autophagy leads to increased Fap-1 and decreased Fas induced apoptosis.  
Additionally, autophagic machinery dictate the cell death mechanism, and inhibition of 
autophagy can alter the mechanism of cell death (Goodall et al., 2016). Thus, it may be necessary 
to understand the mechanism of cell-death associated with therapies to determine which 
therapies would benefit from autophagy inhibition. 
Additionally, autophagy inhibition may alter an antitumoral T cell response. Dying cells 
secrete ATP in an autophagy dependent mechanism, and secreted ATP acts as a mitogen to 
enhance cytotoxic T cells (Y. Ma, Galluzzi, Zitvogel, & Kroemer, 2013). In some instances, 
autophagy inhibition in animal models with a fully intact immune system lead to poorer 
outcomes compared to not inhibiting autophagy (Michaud et al., 2011). Supporting this concept, 
caloric restriction, a known autophagy inducer, potentiates the effects of chemotherapy 
(Pietrocola et al., 2016). In addition, vitamin E derivatives, which also induce autophagy, 
potentiate the effects of chemotherapy (Y. Li et al., 2012). However, this seems to depend on the 
tumor model used, as autophagy inhibition also potentiates the effects of therapy in other 





strategy in an immunocompetent model would likely have better predictive power as to the 
potential clinical response. 
Despite the role of autophagy in mediating different cell death pathways, and altering the 
immune response, the vast majority of evidence points to autophagy inhibition as a strong 
candidate for clinical trial. Many cancers depend on autophagy for survival. For example, 
cancers with mutated Ras require a high basal level of autophagy for their sustained growth (Guo 
et al., 2011). This stands true for cancers with a high activation of STAT3 (Maycotte et al., 
2014). Although direct confirmation of this in HNSCC is still needed, a high proportion of 
HNSCC patients have mutant Ras and overexpressed STAT3 (Rothenberg & Ellisen, 2012; Sen 
et al., 2015). Our work demonstrates the role of autophagy inhibition in potentiating the effects 
of cisplatin. This is supported in other cancer types, such as lung, bladder, and melanoma (Levy 
et al., 2017). This indicates autophagy inhibition would potentiate the effects of therapy in 
HNSCC. 
Beyond the carcinoma cells, autophagy inhibition would alter the microenvironmental 
contributions to this disease. Our work demonstrates the role of autophagy dependent secretion 
in the microenvironment. Other groups also demonstrate how microenvironment autophagy 
would contribute to disease progression (Sousa et al., 2016) (Endo et al., 2017). Thus, autophagy 
inhibition would normalize a highly active microenvironment, and likely reduce 
microenvironmental contributions to disease progression. 
All of this points to autophagy inhibition as improving patient outcomes. Yet, although 
the first report of autophagy as a therapeutic strategy came about more than 10 years ago 
(Amaravadi et al., 2007), autophagy inhibitors have not reached patients. The lack of a targeted 





Need for a Selective Autophagy inhibitor 
CQ and HCQ offer safe methods of targeting the lysosome. However, high doses are 
necessary to achieve accumulation of autophagosomes within patient cells (Rangwala et al., 
2014). Additionally, CQ targets the lysosome, an important component of degradative 
autophagy, but a component that may not be necessary for autophagy dependent secretion. 
Beyond CQ, few other inhibitors targeting the autophagy pathway have minimal adverse effects 
when given at doses necessary for autophagy inhibition in patients. 
There is a need for selective autophagy inhibition. Current inhibitors primarily target the 
lysosome or upstream kinases. However, few that are widely used are selective. The only one to 
date that demonstrates potent and selective inhibition of autophagy is SAR405 (Ronan et al., 
2014). As such, we used this selective inhibitor in our studies. Our results indicate that SAR405 
has a better therapeutic effect compared to CQ as a single agent, and potentiates the effects of 
cisplatin better than CQ. This indicates that selective and potent inhibition of autophagy would 
result in better outcomes for patients.  
However, our animal trial is the only trial to date that assesses the role of SAR405 in an 
animal model. Other Vps34 inhibitors by the same group that developed SAR405 demonstrate 
kinase inhibition in vivo, but these have not been assessed in terms of autophagic flux inhibition 
(B. Pasquier et al., 2015). Additionally, Vps34 has other functions outside of the autophagy 
pathway, as it also regulates endosomal trafficking (E. E. Johnson et al., 2006).  Thus, there is a 
need for even more selective autophagy inhibition. 
Future studies should direct attention towards inhibiting autophagic flux specific events. 





be a great direction for future therapy. The dearth of therapeutics targeting this pathway creates a 
molecular frontier in which discovery might occur. 
Additionally, there is need for a selective inhibitor that differentiates secretory and 
degradative autophagy. Current inhibitors inhibit both functions of the autophagic machinery. 
Inhibition of either secretory or degradative pathways would better define what molecular 
substrates are chaperoned in an autophagy dependent manner. A selective inhibitor would also 
allow for targeted inhibition of the secretory functions of fibroblasts that we observed in our 
data. The main obstacle in developing a selective inhibitor is the lack of mechanistic 
understanding of the autophagy dependent secretion pathway. Future studies dissecting the 
mechanisms of these pathways will provide increased selectivity of inhibitors. 
Autophagy: An Activated Fibroblast Marker? 
Our results from current and past studies demonstrate a role for activated CAFs in 
supporting tumor progression. CAFs are phenotypically different from NFs, and have a much 
greater influence on disease. However, despite this understanding, the lexicon describing 
activated fibroblasts is short. α-SMA is the most widely used marker of activated fibroblasts 
(Hinz et al., 2007). This is known to be induced by TGF-β (Lewis et al., 2004), and is present in 
our CAFs (Wheeler et al., 2014). A marker less frequently used is FAP (Fibroblast Activation 
Protein) (Park et al., 1999). This is widely expressed in CAFs of multiple cancer types (Lee et 
al., 2011), and high expression of FAP associates with poor prognosis for HNSCC patients (H. 
Wang et al., 2014). Beyond these two, few other markers distinguish an activated fibroblast from 
a “normal” fibroblast. 
Autophagy might provide an additional descriptor of an activated fibroblast. Our results 
indicate CAFs have a much greater basal level of autophagy. Upon autophagy inhibition, the role 





autophagy seems to be of importance in regulating a stem-like phenotype in fibroblasts (S. Wang 
et al., 2013). Given these findings, our work sheds light on a previously unrecognized role for 
autophagy in fibroblast activation. 
Conclusions 
This work reveals unexpected roles for the supporting stroma and autophagy in HNSCC.  
The dearth of HNSCC therapeutics that translate from bench to bedside prompted us to 
investigate microenvironment components that contribute to disease progression. As CAFs are 
the most abundant microenvironment cell type, and are well known to support tumor 
progression, we set out to understand the underlying biology of these cells. 
To our surprise, CAFs have significantly more autophagic flux compared to NFs. Before 
these studies, autophagy connoted a mechanism of cell death and degradation to most cancer 
biologists. Nevertheless, CAFs proliferate quickly, despite a high basal level of autophagy. 
Autophagy inhibition mitigates CAF secretion of factors important for cancer progression, 
indicating an autophagy dependent secretome. This reveals that in CAFs, and likely other cell 
types, autophagy machinery is involved in cellular secretion within the HNSCC 
microenvironment. 
Intriguingly, we found that tumor cells induce autophagy in CAFs, hijacking the 
microenvironment to promote disease progression. This creates a positive, symbiotic loop 
between HNSCC and CAFs, which promotes increased autophagy in both cell types. These 
findings reveal the potential therapeutic strategy of targeting autophagy in HNSCC. Our 
resulting data from both in vitro and in vivo studies using combined HNSCC-CAF models 





studies described offer a new therapeutic strategy in HNSCC, and insights into the biology of 
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Low Magnification Images 
This appendix provides low magnification images of higher powered magnification transmission electron 
















Figure 4.1b-CAFs Demonstrate Increased Autophagosomes than NFs 

















Figure 4.4b - CAFs Demonstrate More LC3 Puncta than NFs 
Representative immunofluorescent of LC3 (green) puncta, Hoechst nuclear stain (blue), 














Figure 5.1b – HNSCC Induces LC3 Puncta in Fibroblasts 
Representative IF of NFs in a 1:1 co-culture with HNSCC (HN5) with and without CQ (80 µM 

















Figure 5.5b – bFGF Induces LC3 Puncta in NFs 
Expanded view (10X) of NF with and without bFGF (100ng/mL) and or CQ (80 µM for last 2 














Figure 5.6b – HNSCC bFGF Mediates NF LC3 Puncta Induction 
Expanded view (20X) of NF alone or co-cultured with either control siRNA (siCon) or bFGF 
siRNA (sibFGF) transfected HNSCC (HN5) for 24 h in 1:1 ratio, and CQ (80 µM for last 2 h); 
LC3 (green), cytokeratin 14 (red), Hoescht nuclear (blue). 
 
